After-Hours Stock Movers: ERYTECH Pharma shares jumped 140%_老虎社区_美港股上老虎

After-Hours Stock Movers: ERYTECH Pharma shares jumped 140%

StreetInsider2021-07-30

After-Hours Stock Movers:

ERYTECH Pharma (Nasdaq: ERYP) 140% HIGHER; announced that the U.S. Food and Drug Administration (FDA) has granted eryaspase Fast Track designation for the treatment of acute lymphocytic leukemia (ALL) patients who have developed hypersensitivity reactions to E. coli-derived pegylated asparaginase (PEG-ASNase).

Atlassian (NASDAQ: TEAM) 13.2% HIGHER; reported Q4 EPS of $0.24, $0.06 better than the analyst estimate of $0.18. Revenue for the quarter came in at $560 million versus the consensus estimate of $524.09 million. Atlassian sees Q1 2022 EPS of $0.38-$0.39, versus the consensus of $0.31. Atlassian sees Q1 2022 revenue of $575-590 million, versus the consensus of $540.89 million.

Misonix, Inc. (Nasdaq: MSON) 12% HIGHER; Bioventus Inc. (Nasdaq: BVS) (Bioventus), a global leader in innovations for active healing, and Misonix, Inc. (Nasdaq: MSON) (Misonix), a provider of minimally invasive therapeutic ultrasonic technologies and regenerative medicine that enhance clinical outcomes, today announced that they have entered into a definitive agreement by which Bioventus will acquire Misonix in a cash-and-stock transaction.

Zynex, Inc. (NASDAQ: ZYXI) 11% LOWER; reported Q2 EPS of $0.08, $0.02 better than the analyst estimate of $0.06. Revenue for the quarter came in at $31 million versus the consensus estimate of $31.31 million.

Zendesk (NYSE: ZEN) 7% LOWER; reported Q2 EPS of $0.13, $0.03 worse than the analyst estimate of $0.16. Revenue for the quarter came in at $318.2 million versus the consensus estimate of $319.79 million. Zendesk sees FY2021 revenue of $1.31-1.32 billion, versus the consensus of $1.31 billion. Zendesk sees Q3 2021 revenue of $332-337 billion, versus the consensus of $335.5 billion.

Skyworks Solutions (NASDAQ: SWKS) 5.2% LOWER; reported Q3 EPS of $2.15, $0.01 better than the analyst estimate of $2.14. Revenue for the quarter came in at $1.12 billion versus the consensus estimate of $1.1 billion. Skyworks Solutions sees Q4 2021 EPS of $2.53-$2.48. Skyworks Solutions sees Q4 2021 revenue of $1.27-1.33 billion, versus the consensus of $1.22 billion.

DexCom (NASDAQ: DXCM) 4.3% HIGHER; reported Q2 EPS of $0.76, $0.31 better than the analyst estimate of $0.45. Revenue for the quarter came in at $59.5 million versus the consensus estimate of $551.27 million. DexCom sees FY2021 revenue of $2.35-2.4 billion, versus the consensus of $2.34 billion.

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

238

Kencom
·2021-07-30
This is a one time hike since 2017 from a high $30.56 down to $4.11; rebound to $10.20. Seems it is going to be a high sell off to cash out tonight. Need to study the sustainability of the future earnings.
回复
4
举报
收起
- Kel9670ong:
  yes to understand the share itself
  2021-07-30
  回复
  举报
Val準凖
·2021-07-30
Love Skyworks
回复
1
举报
Leekeez
·2021-07-30
Ok
回复
1
举报
Khairul0802
·2021-07-30
Like
回复
2
举报
DKNY
·2021-07-30
Good. Pls like.
回复
7
举报
收起
- kenong62:
  done
  2021-07-30
  回复
  举报
- Khairul0802:
  Ok
  2021-07-30
  回复
  举报
sSS
·2021-07-30
Like pls
回复
2
举报
Upswing118
·2021-07-30
How nice if the same happened to china based stocks[得意]
回复
3
举报
Mr小白
·2021-07-30
Ohhh
回复
2
举报
PREM
·2021-07-30
Most reliable stocks
回复
5
举报
收起
- junan:
  Yup
  2021-07-30
  回复
  举报
您解释看看
·2021-07-30
[Miser] [Miser]
回复
2
举报
Syin23
·2021-07-30
Omg... Roller coaster.. [惊吓]
回复
3
举报
收起
- Amins:
  Hahah
  2021-07-30
  回复
  举报
KeatWei
·2021-07-30
Like please
回复
4
举报
收起
- 小虎一飞冲天:
  👍🏼
  2021-07-30
  回复
  举报
Ameliakoh
·2021-07-30
Pls like n comment 🙏
回复
9
举报
收起
- KeatWei:
  Okay
  2021-07-30
  回复
  举报
- sSS:
  .
  2021-07-30
  回复
  举报
- Benly8:
  DonE, Pls like back thanks
  2021-07-31
  回复
  举报
查看更多 2 条评论
Heidit
·2021-07-30
Cool read
回复
3
举报
Hesliut
·2021-07-30
Like please~
回复
3
举报
Blurking
·2021-07-30
Good news for investor and patients
回复
5
举报
收起
- Hesliut:
  Agree!
  2021-07-30
  回复
  举报
June陈
·2021-07-30
Power.
回复
3
举报
FrederickL
·2021-07-30
Great!
回复
2
举报
FuHeng
·2021-07-30
Cool!
回复
2
举报
lewisleeks
·2021-07-30
Great[Smile]
回复
3
举报

热议股票

7x24

全部

{"i18n":{"language":"zh_CN"},"data":{"share":"https://ttm.financial/m/news/2155182860?lang=zh_CN&edition=full","thumbnail":"","is_english":true,"pubTime":"2021-07-30 07:57","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2155182860","market":"us","top_or_hot":-1,"title":"After-Hours Stock Movers: ERYTECH Pharma shares jumped 140%","media":"StreetInsider","content":"<p>After-Hours Stock Movers:</p>\n<p>ERYTECH Pharma (Nasdaq: ERYP) 140% HIGHER; announced that the U.S. Food and Drug Administration (FDA) has granted eryaspase Fast Track designation for the treatment of acute lymphocytic leukemia (ALL) patients who have developed hypersensitivity reactions to E. coli-derived pegylated asparaginase (PEG-ASNase).</p>\n<p>Atlassian (NASDAQ: TEAM) 13.2% HIGHER; reported Q4 EPS of $0.24, $0.06 better than the analyst estimate of $0.18. Revenue for the quarter came in at $560 million versus the consensus estimate of $524.09 million. Atlassian sees Q1 2022 EPS of $0.38-$0.39, versus the consensus of $0.31. Atlassian sees Q1 2022 revenue of $575-590 million, versus the consensus of $540.89 million.</p>\n<p>Misonix, Inc. (Nasdaq: MSON) 12% HIGHER; <a href=\"https://laohu8.com/S/BIOV\">Bioventus Inc.</a> (Nasdaq: BVS) (Bioventus), a global leader in innovations for active healing, and Misonix, Inc. (Nasdaq: MSON) (Misonix), a provider of minimally invasive therapeutic ultrasonic technologies and regenerative medicine that enhance clinical outcomes, today announced that they have entered into a definitive agreement by which Bioventus will acquire Misonix in a cash-and-stock transaction.</p>\n<p><a href=\"https://laohu8.com/S/ZYXI\">Zynex, Inc.</a> (NASDAQ: ZYXI) 11% LOWER; reported Q2 EPS of $0.08, $0.02 better than the analyst estimate of $0.06. Revenue for the quarter came in at $31 million versus the consensus estimate of $31.31 million.</p>\n<p>Zendesk (NYSE: ZEN) 7% LOWER; reported Q2 EPS of $0.13, $0.03 worse than the analyst estimate of $0.16. Revenue for the quarter came in at $318.2 million versus the consensus estimate of $319.79 million. Zendesk sees FY2021 revenue of $1.31-1.32 billion, versus the consensus of $1.31 billion. Zendesk sees Q3 2021 revenue of $332-337 billion, versus the consensus of $335.5 billion.</p>\n<p>Skyworks Solutions (NASDAQ: SWKS) 5.2% LOWER; reported Q3 EPS of $2.15, $0.01 better than the analyst estimate of $2.14. Revenue for the quarter came in at $1.12 billion versus the consensus estimate of $1.1 billion. Skyworks Solutions sees Q4 2021 EPS of $2.53-$2.48. Skyworks Solutions sees Q4 2021 revenue of $1.27-1.33 billion, versus the consensus of $1.22 billion.</p>\n<p>DexCom (NASDAQ: DXCM) 4.3% HIGHER; reported Q2 EPS of $0.76, $0.31 better than the analyst estimate of $0.45. Revenue for the quarter came in at $59.5 million versus the consensus estimate of $551.27 million. DexCom sees FY2021 revenue of $2.35-2.4 billion, versus the consensus of $2.34 billion.</p>","source":"highlight_streetinsider","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>After-Hours Stock Movers: ERYTECH Pharma shares jumped 140%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAfter-Hours Stock Movers: ERYTECH Pharma shares jumped 140%\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-30 07:57 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.streetinsider.com/dr/news.php?id=18744154><strong>StreetInsider</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>After-Hours Stock Movers:\nERYTECH Pharma (Nasdaq: ERYP) 140% HIGHER; announced that the U.S. Food and Drug Administration (FDA) has granted eryaspase Fast Track designation for the treatment of acute ...</p>\n\n<a href=\"https://www.streetinsider.com/dr/news.php?id=18744154\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"DXCM","symbol_name":"德康医疗","start_time":0,"source_url":"https://www.streetinsider.com/dr/news.php?id=18744154","article_id":"2155182860","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2155182860","pubTimestamp":1627603020,"columns":[],"sourceInfo":{"source_id":"highlight_streetinsider","name":"StreetInsider"},"weMediaInfo":null,"summary":"After-Hours Stock Movers:\nERYTECH Pharma (Nasdaq: ERYP) 140% HIGHER; announced that the U.S. Food an","collect":0,"end_time":0,"defaultTopTitle":"streetinsider.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"DXCM":"德康医疗","TEAM":"Atlassian Corporation PLC","MSON":"Misonix Inc","SWKS":"思佳讯","ZYXI":"Zynex, Inc."},"translate_title":"盘后股价上涨：ERYTECH Pharma股价上涨140%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"DXCM":0.9,"ERYP":0.9,"MSON":0.9,"SWKS":0.9,"TEAM":0.9,"ZEN":0.9,"ZYXI":0.9},"content_text":"After-Hours Stock Movers:\nERYTECH Pharma (Nasdaq: ERYP) 140% HIGHER; announced that the U.S. Food and Drug Administration (FDA) has granted eryaspase Fast Track designation for the treatment of acute lymphocytic leukemia (ALL) patients who have developed hypersensitivity reactions to E. coli-derived pegylated asparaginase (PEG-ASNase).\nAtlassian (NASDAQ: TEAM) 13.2% HIGHER; reported Q4 EPS of $0.24, $0.06 better than the analyst estimate of $0.18. Revenue for the quarter came in at $560 million versus the consensus estimate of $524.09 million. Atlassian sees Q1 2022 EPS of $0.38-$0.39, versus the consensus of $0.31. Atlassian sees Q1 2022 revenue of $575-590 million, versus the consensus of $540.89 million.\nMisonix, Inc. (Nasdaq: MSON) 12% HIGHER; Bioventus Inc. (Nasdaq: BVS) (Bioventus), a global leader in innovations for active healing, and Misonix, Inc. (Nasdaq: MSON) (Misonix), a provider of minimally invasive therapeutic ultrasonic technologies and regenerative medicine that enhance clinical outcomes, today announced that they have entered into a definitive agreement by which Bioventus will acquire Misonix in a cash-and-stock transaction.\nZynex, Inc. (NASDAQ: ZYXI) 11% LOWER; reported Q2 EPS of $0.08, $0.02 better than the analyst estimate of $0.06. Revenue for the quarter came in at $31 million versus the consensus estimate of $31.31 million.\nZendesk (NYSE: ZEN) 7% LOWER; reported Q2 EPS of $0.13, $0.03 worse than the analyst estimate of $0.16. Revenue for the quarter came in at $318.2 million versus the consensus estimate of $319.79 million. Zendesk sees FY2021 revenue of $1.31-1.32 billion, versus the consensus of $1.31 billion. Zendesk sees Q3 2021 revenue of $332-337 billion, versus the consensus of $335.5 billion.\nSkyworks Solutions (NASDAQ: SWKS) 5.2% LOWER; reported Q3 EPS of $2.15, $0.01 better than the analyst estimate of $2.14. Revenue for the quarter came in at $1.12 billion versus the consensus estimate of $1.1 billion. Skyworks Solutions sees Q4 2021 EPS of $2.53-$2.48. Skyworks Solutions sees Q4 2021 revenue of $1.27-1.33 billion, versus the consensus of $1.22 billion.\nDexCom (NASDAQ: DXCM) 4.3% HIGHER; reported Q2 EPS of $0.76, $0.31 better than the analyst estimate of $0.45. Revenue for the quarter came in at $59.5 million versus the consensus estimate of $551.27 million. DexCom sees FY2021 revenue of $2.35-2.4 billion, versus the consensus of $2.34 billion.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"},"commentList":[{"id":806086795,"gmtCreate":1627616984517,"gmtModify":1631883895752,"author":{"id":"4088748055325860","authorId":"4088748055325860","name":"Kencom","avatar":"https://static.tigerbbs.com/933749ae75c1d77b2cb7a961bacc251f","vip":1,"crmLevel":6,"crmLevelSwitch":0,"idStr":"4088748055325860","authorIdStr":"4088748055325860"},"htmlText":"This is a one time hike since 2017 from a high $30.56 down to $4.11; rebound to $10.20. Seems it is going to be a high sell off to cash out tonight. Need to study the sustainability of the future earnings.","listText":"This is a one time hike since 2017 from a high $30.56 down to $4.11; rebound to $10.20. Seems it is going to be a high sell off to cash out tonight. Need to study the sustainability of the future earnings.","text":"This is a one time hike since 2017 from a high $30.56 down to $4.11; rebound to $10.20. Seems it is going to be a high sell off to cash out tonight. Need to study the sustainability of the future earnings.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/806086795","repostId":2155182860,"repostType":2,"repost":{"id":"2155182860","kind":"news","pubTimestamp":1627603020,"share":"https://ttm.financial/m/news/2155182860?lang=&edition=full","pubTime":"2021-07-30 07:57","market":"us","language":"en","title":"After-Hours Stock Movers: ERYTECH Pharma shares jumped 140%","url":"https://stock-news.laohu8.com/highlight/detail?id=2155182860","media":"StreetInsider","summary":"After-Hours Stock Movers:\nERYTECH Pharma (Nasdaq: ERYP) 140% HIGHER; announced that the U.S. Food an","content":"<p>After-Hours Stock Movers:</p>\n<p>ERYTECH Pharma (Nasdaq: ERYP) 140% HIGHER; announced that the U.S. Food and Drug Administration (FDA) has granted eryaspase Fast Track designation for the treatment of acute lymphocytic leukemia (ALL) patients who have developed hypersensitivity reactions to E. coli-derived pegylated asparaginase (PEG-ASNase).</p>\n<p>Atlassian (NASDAQ: TEAM) 13.2% HIGHER; reported Q4 EPS of $0.24, $0.06 better than the analyst estimate of $0.18. Revenue for the quarter came in at $560 million versus the consensus estimate of $524.09 million. Atlassian sees Q1 2022 EPS of $0.38-$0.39, versus the consensus of $0.31. Atlassian sees Q1 2022 revenue of $575-590 million, versus the consensus of $540.89 million.</p>\n<p>Misonix, Inc. (Nasdaq: MSON) 12% HIGHER; <a href=\"https://laohu8.com/S/BIOV\">Bioventus Inc.</a> (Nasdaq: BVS) (Bioventus), a global leader in innovations for active healing, and Misonix, Inc. (Nasdaq: MSON) (Misonix), a provider of minimally invasive therapeutic ultrasonic technologies and regenerative medicine that enhance clinical outcomes, today announced that they have entered into a definitive agreement by which Bioventus will acquire Misonix in a cash-and-stock transaction.</p>\n<p><a href=\"https://laohu8.com/S/ZYXI\">Zynex, Inc.</a> (NASDAQ: ZYXI) 11% LOWER; reported Q2 EPS of $0.08, $0.02 better than the analyst estimate of $0.06. Revenue for the quarter came in at $31 million versus the consensus estimate of $31.31 million.</p>\n<p>Zendesk (NYSE: ZEN) 7% LOWER; reported Q2 EPS of $0.13, $0.03 worse than the analyst estimate of $0.16. Revenue for the quarter came in at $318.2 million versus the consensus estimate of $319.79 million. Zendesk sees FY2021 revenue of $1.31-1.32 billion, versus the consensus of $1.31 billion. Zendesk sees Q3 2021 revenue of $332-337 billion, versus the consensus of $335.5 billion.</p>\n<p>Skyworks Solutions (NASDAQ: SWKS) 5.2% LOWER; reported Q3 EPS of $2.15, $0.01 better than the analyst estimate of $2.14. Revenue for the quarter came in at $1.12 billion versus the consensus estimate of $1.1 billion. Skyworks Solutions sees Q4 2021 EPS of $2.53-$2.48. Skyworks Solutions sees Q4 2021 revenue of $1.27-1.33 billion, versus the consensus of $1.22 billion.</p>\n<p>DexCom (NASDAQ: DXCM) 4.3% HIGHER; reported Q2 EPS of $0.76, $0.31 better than the analyst estimate of $0.45. Revenue for the quarter came in at $59.5 million versus the consensus estimate of $551.27 million. DexCom sees FY2021 revenue of $2.35-2.4 billion, versus the consensus of $2.34 billion.</p>","source":"highlight_streetinsider","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>After-Hours Stock Movers: ERYTECH Pharma shares jumped 140%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAfter-Hours Stock Movers: ERYTECH Pharma shares jumped 140%\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-30 07:57 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.streetinsider.com/dr/news.php?id=18744154><strong>StreetInsider</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>After-Hours Stock Movers:\nERYTECH Pharma (Nasdaq: ERYP) 140% HIGHER; announced that the U.S. Food and Drug Administration (FDA) has granted eryaspase Fast Track designation for the treatment of acute ...</p>\n\n<a href=\"https://www.streetinsider.com/dr/news.php?id=18744154\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"DXCM":"德康医疗","TEAM":"Atlassian Corporation PLC","MSON":"Misonix Inc","SWKS":"思佳讯","ZYXI":"Zynex, Inc."},"source_url":"https://www.streetinsider.com/dr/news.php?id=18744154","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2155182860","content_text":"After-Hours Stock Movers:\nERYTECH Pharma (Nasdaq: ERYP) 140% HIGHER; announced that the U.S. Food and Drug Administration (FDA) has granted eryaspase Fast Track designation for the treatment of acute lymphocytic leukemia (ALL) patients who have developed hypersensitivity reactions to E. coli-derived pegylated asparaginase (PEG-ASNase).\nAtlassian (NASDAQ: TEAM) 13.2% HIGHER; reported Q4 EPS of $0.24, $0.06 better than the analyst estimate of $0.18. Revenue for the quarter came in at $560 million versus the consensus estimate of $524.09 million. Atlassian sees Q1 2022 EPS of $0.38-$0.39, versus the consensus of $0.31. Atlassian sees Q1 2022 revenue of $575-590 million, versus the consensus of $540.89 million.\nMisonix, Inc. (Nasdaq: MSON) 12% HIGHER; Bioventus Inc. (Nasdaq: BVS) (Bioventus), a global leader in innovations for active healing, and Misonix, Inc. (Nasdaq: MSON) (Misonix), a provider of minimally invasive therapeutic ultrasonic technologies and regenerative medicine that enhance clinical outcomes, today announced that they have entered into a definitive agreement by which Bioventus will acquire Misonix in a cash-and-stock transaction.\nZynex, Inc. (NASDAQ: ZYXI) 11% LOWER; reported Q2 EPS of $0.08, $0.02 better than the analyst estimate of $0.06. Revenue for the quarter came in at $31 million versus the consensus estimate of $31.31 million.\nZendesk (NYSE: ZEN) 7% LOWER; reported Q2 EPS of $0.13, $0.03 worse than the analyst estimate of $0.16. Revenue for the quarter came in at $318.2 million versus the consensus estimate of $319.79 million. Zendesk sees FY2021 revenue of $1.31-1.32 billion, versus the consensus of $1.31 billion. Zendesk sees Q3 2021 revenue of $332-337 billion, versus the consensus of $335.5 billion.\nSkyworks Solutions (NASDAQ: SWKS) 5.2% LOWER; reported Q3 EPS of $2.15, $0.01 better than the analyst estimate of $2.14. Revenue for the quarter came in at $1.12 billion versus the consensus estimate of $1.1 billion. Skyworks Solutions sees Q4 2021 EPS of $2.53-$2.48. Skyworks Solutions sees Q4 2021 revenue of $1.27-1.33 billion, versus the consensus of $1.22 billion.\nDexCom (NASDAQ: DXCM) 4.3% HIGHER; reported Q2 EPS of $0.76, $0.31 better than the analyst estimate of $0.45. Revenue for the quarter came in at $59.5 million versus the consensus estimate of $551.27 million. DexCom sees FY2021 revenue of $2.35-2.4 billion, versus the consensus of $2.34 billion.","news_type":1,"symbols_score_info":{"DXCM":0.9,"ERYP":0.9,"MSON":0.9,"SWKS":0.9,"TEAM":0.9,"ZEN":0.9,"ZYXI":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5376793,"gmtCreate":1627623777952,"gmtModify":1635164304551,"authorId":3578468158955348,"author":{"id":3578468158955348,"idStr":"3578468158955348","authorId":3578468158955348,"name":"Kel9670ong","avatar":"https://static.tigerbbs.com/bd86c42e207fbd94e7f8877a29457d71","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":806086795,"type":1,"supId":0,"prevId":0,"content":"yes to understand the share itself","text":"yes to understand the share itself","html":"yes to understand the share itself"}],"langContent":"EN"},{"id":806086341,"gmtCreate":1627616927683,"gmtModify":1633757721668,"author":{"id":"3581556348949722","authorId":"3581556348949722","name":"Val準凖","avatar":"https://static.tigerbbs.com/fc78ba8079eaf21b89d9286a3857c533","vip":1,"crmLevel":4,"crmLevelSwitch":0,"idStr":"3581556348949722","authorIdStr":"3581556348949722"},"htmlText":"Love Skyworks&nbsp;","listText":"Love Skyworks&nbsp;","text":"Love Skyworks","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/806086341","repostId":2155182860,"repostType":2,"repost":{"id":"2155182860","kind":"news","pubTimestamp":1627603020,"share":"https://ttm.financial/m/news/2155182860?lang=&edition=full","pubTime":"2021-07-30 07:57","market":"us","language":"en","title":"After-Hours Stock Movers: ERYTECH Pharma shares jumped 140%","url":"https://stock-news.laohu8.com/highlight/detail?id=2155182860","media":"StreetInsider","summary":"After-Hours Stock Movers:\nERYTECH Pharma (Nasdaq: ERYP) 140% HIGHER; announced that the U.S. Food an","content":"<p>After-Hours Stock Movers:</p>\n<p>ERYTECH Pharma (Nasdaq: ERYP) 140% HIGHER; announced that the U.S. Food and Drug Administration (FDA) has granted eryaspase Fast Track designation for the treatment of acute lymphocytic leukemia (ALL) patients who have developed hypersensitivity reactions to E. coli-derived pegylated asparaginase (PEG-ASNase).</p>\n<p>Atlassian (NASDAQ: TEAM) 13.2% HIGHER; reported Q4 EPS of $0.24, $0.06 better than the analyst estimate of $0.18. Revenue for the quarter came in at $560 million versus the consensus estimate of $524.09 million. Atlassian sees Q1 2022 EPS of $0.38-$0.39, versus the consensus of $0.31. Atlassian sees Q1 2022 revenue of $575-590 million, versus the consensus of $540.89 million.</p>\n<p>Misonix, Inc. (Nasdaq: MSON) 12% HIGHER; <a href=\"https://laohu8.com/S/BIOV\">Bioventus Inc.</a> (Nasdaq: BVS) (Bioventus), a global leader in innovations for active healing, and Misonix, Inc. (Nasdaq: MSON) (Misonix), a provider of minimally invasive therapeutic ultrasonic technologies and regenerative medicine that enhance clinical outcomes, today announced that they have entered into a definitive agreement by which Bioventus will acquire Misonix in a cash-and-stock transaction.</p>\n<p><a href=\"https://laohu8.com/S/ZYXI\">Zynex, Inc.</a> (NASDAQ: ZYXI) 11% LOWER; reported Q2 EPS of $0.08, $0.02 better than the analyst estimate of $0.06. Revenue for the quarter came in at $31 million versus the consensus estimate of $31.31 million.</p>\n<p>Zendesk (NYSE: ZEN) 7% LOWER; reported Q2 EPS of $0.13, $0.03 worse than the analyst estimate of $0.16. Revenue for the quarter came in at $318.2 million versus the consensus estimate of $319.79 million. Zendesk sees FY2021 revenue of $1.31-1.32 billion, versus the consensus of $1.31 billion. Zendesk sees Q3 2021 revenue of $332-337 billion, versus the consensus of $335.5 billion.</p>\n<p>Skyworks Solutions (NASDAQ: SWKS) 5.2% LOWER; reported Q3 EPS of $2.15, $0.01 better than the analyst estimate of $2.14. Revenue for the quarter came in at $1.12 billion versus the consensus estimate of $1.1 billion. Skyworks Solutions sees Q4 2021 EPS of $2.53-$2.48. Skyworks Solutions sees Q4 2021 revenue of $1.27-1.33 billion, versus the consensus of $1.22 billion.</p>\n<p>DexCom (NASDAQ: DXCM) 4.3% HIGHER; reported Q2 EPS of $0.76, $0.31 better than the analyst estimate of $0.45. Revenue for the quarter came in at $59.5 million versus the consensus estimate of $551.27 million. DexCom sees FY2021 revenue of $2.35-2.4 billion, versus the consensus of $2.34 billion.</p>","source":"highlight_streetinsider","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>After-Hours Stock Movers: ERYTECH Pharma shares jumped 140%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAfter-Hours Stock Movers: ERYTECH Pharma shares jumped 140%\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-30 07:57 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.streetinsider.com/dr/news.php?id=18744154><strong>StreetInsider</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>After-Hours Stock Movers:\nERYTECH Pharma (Nasdaq: ERYP) 140% HIGHER; announced that the U.S. Food and Drug Administration (FDA) has granted eryaspase Fast Track designation for the treatment of acute ...</p>\n\n<a href=\"https://www.streetinsider.com/dr/news.php?id=18744154\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"DXCM":"德康医疗","TEAM":"Atlassian Corporation PLC","MSON":"Misonix Inc","SWKS":"思佳讯","ZYXI":"Zynex, Inc."},"source_url":"https://www.streetinsider.com/dr/news.php?id=18744154","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2155182860","content_text":"After-Hours Stock Movers:\nERYTECH Pharma (Nasdaq: ERYP) 140% HIGHER; announced that the U.S. Food and Drug Administration (FDA) has granted eryaspase Fast Track designation for the treatment of acute lymphocytic leukemia (ALL) patients who have developed hypersensitivity reactions to E. coli-derived pegylated asparaginase (PEG-ASNase).\nAtlassian (NASDAQ: TEAM) 13.2% HIGHER; reported Q4 EPS of $0.24, $0.06 better than the analyst estimate of $0.18. Revenue for the quarter came in at $560 million versus the consensus estimate of $524.09 million. Atlassian sees Q1 2022 EPS of $0.38-$0.39, versus the consensus of $0.31. Atlassian sees Q1 2022 revenue of $575-590 million, versus the consensus of $540.89 million.\nMisonix, Inc. (Nasdaq: MSON) 12% HIGHER; Bioventus Inc. (Nasdaq: BVS) (Bioventus), a global leader in innovations for active healing, and Misonix, Inc. (Nasdaq: MSON) (Misonix), a provider of minimally invasive therapeutic ultrasonic technologies and regenerative medicine that enhance clinical outcomes, today announced that they have entered into a definitive agreement by which Bioventus will acquire Misonix in a cash-and-stock transaction.\nZynex, Inc. (NASDAQ: ZYXI) 11% LOWER; reported Q2 EPS of $0.08, $0.02 better than the analyst estimate of $0.06. Revenue for the quarter came in at $31 million versus the consensus estimate of $31.31 million.\nZendesk (NYSE: ZEN) 7% LOWER; reported Q2 EPS of $0.13, $0.03 worse than the analyst estimate of $0.16. Revenue for the quarter came in at $318.2 million versus the consensus estimate of $319.79 million. Zendesk sees FY2021 revenue of $1.31-1.32 billion, versus the consensus of $1.31 billion. Zendesk sees Q3 2021 revenue of $332-337 billion, versus the consensus of $335.5 billion.\nSkyworks Solutions (NASDAQ: SWKS) 5.2% LOWER; reported Q3 EPS of $2.15, $0.01 better than the analyst estimate of $2.14. Revenue for the quarter came in at $1.12 billion versus the consensus estimate of $1.1 billion. Skyworks Solutions sees Q4 2021 EPS of $2.53-$2.48. Skyworks Solutions sees Q4 2021 revenue of $1.27-1.33 billion, versus the consensus of $1.22 billion.\nDexCom (NASDAQ: DXCM) 4.3% HIGHER; reported Q2 EPS of $0.76, $0.31 better than the analyst estimate of $0.45. Revenue for the quarter came in at $59.5 million versus the consensus estimate of $551.27 million. DexCom sees FY2021 revenue of $2.35-2.4 billion, versus the consensus of $2.34 billion.","news_type":1,"symbols_score_info":{"DXCM":0.9,"ERYP":0.9,"MSON":0.9,"SWKS":0.9,"TEAM":0.9,"ZEN":0.9,"ZYXI":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":806081255,"gmtCreate":1627616760377,"gmtModify":1633757722982,"author":{"id":"4089085863454690","authorId":"4089085863454690","name":"Leekeez","avatar":"https://static.tigerbbs.com/0dc7b69aff39f86a9dc2217fe596c9af","vip":1,"crmLevel":4,"crmLevelSwitch":0,"idStr":"4089085863454690","authorIdStr":"4089085863454690"},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/806081255","repostId":2155182860,"repostType":4,"repost":{"id":"2155182860","kind":"news","pubTimestamp":1627603020,"share":"https://ttm.financial/m/news/2155182860?lang=&edition=full","pubTime":"2021-07-30 07:57","market":"us","language":"en","title":"After-Hours Stock Movers: ERYTECH Pharma shares jumped 140%","url":"https://stock-news.laohu8.com/highlight/detail?id=2155182860","media":"StreetInsider","summary":"After-Hours Stock Movers:\nERYTECH Pharma (Nasdaq: ERYP) 140% HIGHER; announced that the U.S. Food an","content":"<p>After-Hours Stock Movers:</p>\n<p>ERYTECH Pharma (Nasdaq: ERYP) 140% HIGHER; announced that the U.S. Food and Drug Administration (FDA) has granted eryaspase Fast Track designation for the treatment of acute lymphocytic leukemia (ALL) patients who have developed hypersensitivity reactions to E. coli-derived pegylated asparaginase (PEG-ASNase).</p>\n<p>Atlassian (NASDAQ: TEAM) 13.2% HIGHER; reported Q4 EPS of $0.24, $0.06 better than the analyst estimate of $0.18. Revenue for the quarter came in at $560 million versus the consensus estimate of $524.09 million. Atlassian sees Q1 2022 EPS of $0.38-$0.39, versus the consensus of $0.31. Atlassian sees Q1 2022 revenue of $575-590 million, versus the consensus of $540.89 million.</p>\n<p>Misonix, Inc. (Nasdaq: MSON) 12% HIGHER; <a href=\"https://laohu8.com/S/BIOV\">Bioventus Inc.</a> (Nasdaq: BVS) (Bioventus), a global leader in innovations for active healing, and Misonix, Inc. (Nasdaq: MSON) (Misonix), a provider of minimally invasive therapeutic ultrasonic technologies and regenerative medicine that enhance clinical outcomes, today announced that they have entered into a definitive agreement by which Bioventus will acquire Misonix in a cash-and-stock transaction.</p>\n<p><a href=\"https://laohu8.com/S/ZYXI\">Zynex, Inc.</a> (NASDAQ: ZYXI) 11% LOWER; reported Q2 EPS of $0.08, $0.02 better than the analyst estimate of $0.06. Revenue for the quarter came in at $31 million versus the consensus estimate of $31.31 million.</p>\n<p>Zendesk (NYSE: ZEN) 7% LOWER; reported Q2 EPS of $0.13, $0.03 worse than the analyst estimate of $0.16. Revenue for the quarter came in at $318.2 million versus the consensus estimate of $319.79 million. Zendesk sees FY2021 revenue of $1.31-1.32 billion, versus the consensus of $1.31 billion. Zendesk sees Q3 2021 revenue of $332-337 billion, versus the consensus of $335.5 billion.</p>\n<p>Skyworks Solutions (NASDAQ: SWKS) 5.2% LOWER; reported Q3 EPS of $2.15, $0.01 better than the analyst estimate of $2.14. Revenue for the quarter came in at $1.12 billion versus the consensus estimate of $1.1 billion. Skyworks Solutions sees Q4 2021 EPS of $2.53-$2.48. Skyworks Solutions sees Q4 2021 revenue of $1.27-1.33 billion, versus the consensus of $1.22 billion.</p>\n<p>DexCom (NASDAQ: DXCM) 4.3% HIGHER; reported Q2 EPS of $0.76, $0.31 better than the analyst estimate of $0.45. Revenue for the quarter came in at $59.5 million versus the consensus estimate of $551.27 million. DexCom sees FY2021 revenue of $2.35-2.4 billion, versus the consensus of $2.34 billion.</p>","source":"highlight_streetinsider","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>After-Hours Stock Movers: ERYTECH Pharma shares jumped 140%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAfter-Hours Stock Movers: ERYTECH Pharma shares jumped 140%\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-30 07:57 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.streetinsider.com/dr/news.php?id=18744154><strong>StreetInsider</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>After-Hours Stock Movers:\nERYTECH Pharma (Nasdaq: ERYP) 140% HIGHER; announced that the U.S. Food and Drug Administration (FDA) has granted eryaspase Fast Track designation for the treatment of acute ...</p>\n\n<a href=\"https://www.streetinsider.com/dr/news.php?id=18744154\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"DXCM":"德康医疗","TEAM":"Atlassian Corporation PLC","MSON":"Misonix Inc","SWKS":"思佳讯","ZYXI":"Zynex, Inc."},"source_url":"https://www.streetinsider.com/dr/news.php?id=18744154","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2155182860","content_text":"After-Hours Stock Movers:\nERYTECH Pharma (Nasdaq: ERYP) 140% HIGHER; announced that the U.S. Food and Drug Administration (FDA) has granted eryaspase Fast Track designation for the treatment of acute lymphocytic leukemia (ALL) patients who have developed hypersensitivity reactions to E. coli-derived pegylated asparaginase (PEG-ASNase).\nAtlassian (NASDAQ: TEAM) 13.2% HIGHER; reported Q4 EPS of $0.24, $0.06 better than the analyst estimate of $0.18. Revenue for the quarter came in at $560 million versus the consensus estimate of $524.09 million. Atlassian sees Q1 2022 EPS of $0.38-$0.39, versus the consensus of $0.31. Atlassian sees Q1 2022 revenue of $575-590 million, versus the consensus of $540.89 million.\nMisonix, Inc. (Nasdaq: MSON) 12% HIGHER; Bioventus Inc. (Nasdaq: BVS) (Bioventus), a global leader in innovations for active healing, and Misonix, Inc. (Nasdaq: MSON) (Misonix), a provider of minimally invasive therapeutic ultrasonic technologies and regenerative medicine that enhance clinical outcomes, today announced that they have entered into a definitive agreement by which Bioventus will acquire Misonix in a cash-and-stock transaction.\nZynex, Inc. (NASDAQ: ZYXI) 11% LOWER; reported Q2 EPS of $0.08, $0.02 better than the analyst estimate of $0.06. Revenue for the quarter came in at $31 million versus the consensus estimate of $31.31 million.\nZendesk (NYSE: ZEN) 7% LOWER; reported Q2 EPS of $0.13, $0.03 worse than the analyst estimate of $0.16. Revenue for the quarter came in at $318.2 million versus the consensus estimate of $319.79 million. Zendesk sees FY2021 revenue of $1.31-1.32 billion, versus the consensus of $1.31 billion. Zendesk sees Q3 2021 revenue of $332-337 billion, versus the consensus of $335.5 billion.\nSkyworks Solutions (NASDAQ: SWKS) 5.2% LOWER; reported Q3 EPS of $2.15, $0.01 better than the analyst estimate of $2.14. Revenue for the quarter came in at $1.12 billion versus the consensus estimate of $1.1 billion. Skyworks Solutions sees Q4 2021 EPS of $2.53-$2.48. Skyworks Solutions sees Q4 2021 revenue of $1.27-1.33 billion, versus the consensus of $1.22 billion.\nDexCom (NASDAQ: DXCM) 4.3% HIGHER; reported Q2 EPS of $0.76, $0.31 better than the analyst estimate of $0.45. Revenue for the quarter came in at $59.5 million versus the consensus estimate of $551.27 million. DexCom sees FY2021 revenue of $2.35-2.4 billion, versus the consensus of $2.34 billion.","news_type":1,"symbols_score_info":{"DXCM":0.9,"ERYP":0.9,"MSON":0.9,"SWKS":0.9,"TEAM":0.9,"ZEN":0.9,"ZYXI":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":806038929,"gmtCreate":1627615501861,"gmtModify":1631883857792,"author":{"id":"3573174299397007","authorId":"3573174299397007","name":"Khairul0802","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":1,"crmLevelSwitch":0,"idStr":"3573174299397007","authorIdStr":"3573174299397007"},"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/806038929","repostId":2155182860,"repostType":4,"repost":{"id":"2155182860","kind":"news","pubTimestamp":1627603020,"share":"https://ttm.financial/m/news/2155182860?lang=&edition=full","pubTime":"2021-07-30 07:57","market":"us","language":"en","title":"After-Hours Stock Movers: ERYTECH Pharma shares jumped 140%","url":"https://stock-news.laohu8.com/highlight/detail?id=2155182860","media":"StreetInsider","summary":"After-Hours Stock Movers:\nERYTECH Pharma (Nasdaq: ERYP) 140% HIGHER; announced that the U.S. Food an","content":"<p>After-Hours Stock Movers:</p>\n<p>ERYTECH Pharma (Nasdaq: ERYP) 140% HIGHER; announced that the U.S. Food and Drug Administration (FDA) has granted eryaspase Fast Track designation for the treatment of acute lymphocytic leukemia (ALL) patients who have developed hypersensitivity reactions to E. coli-derived pegylated asparaginase (PEG-ASNase).</p>\n<p>Atlassian (NASDAQ: TEAM) 13.2% HIGHER; reported Q4 EPS of $0.24, $0.06 better than the analyst estimate of $0.18. Revenue for the quarter came in at $560 million versus the consensus estimate of $524.09 million. Atlassian sees Q1 2022 EPS of $0.38-$0.39, versus the consensus of $0.31. Atlassian sees Q1 2022 revenue of $575-590 million, versus the consensus of $540.89 million.</p>\n<p>Misonix, Inc. (Nasdaq: MSON) 12% HIGHER; <a href=\"https://laohu8.com/S/BIOV\">Bioventus Inc.</a> (Nasdaq: BVS) (Bioventus), a global leader in innovations for active healing, and Misonix, Inc. (Nasdaq: MSON) (Misonix), a provider of minimally invasive therapeutic ultrasonic technologies and regenerative medicine that enhance clinical outcomes, today announced that they have entered into a definitive agreement by which Bioventus will acquire Misonix in a cash-and-stock transaction.</p>\n<p><a href=\"https://laohu8.com/S/ZYXI\">Zynex, Inc.</a> (NASDAQ: ZYXI) 11% LOWER; reported Q2 EPS of $0.08, $0.02 better than the analyst estimate of $0.06. Revenue for the quarter came in at $31 million versus the consensus estimate of $31.31 million.</p>\n<p>Zendesk (NYSE: ZEN) 7% LOWER; reported Q2 EPS of $0.13, $0.03 worse than the analyst estimate of $0.16. Revenue for the quarter came in at $318.2 million versus the consensus estimate of $319.79 million. Zendesk sees FY2021 revenue of $1.31-1.32 billion, versus the consensus of $1.31 billion. Zendesk sees Q3 2021 revenue of $332-337 billion, versus the consensus of $335.5 billion.</p>\n<p>Skyworks Solutions (NASDAQ: SWKS) 5.2% LOWER; reported Q3 EPS of $2.15, $0.01 better than the analyst estimate of $2.14. Revenue for the quarter came in at $1.12 billion versus the consensus estimate of $1.1 billion. Skyworks Solutions sees Q4 2021 EPS of $2.53-$2.48. Skyworks Solutions sees Q4 2021 revenue of $1.27-1.33 billion, versus the consensus of $1.22 billion.</p>\n<p>DexCom (NASDAQ: DXCM) 4.3% HIGHER; reported Q2 EPS of $0.76, $0.31 better than the analyst estimate of $0.45. Revenue for the quarter came in at $59.5 million versus the consensus estimate of $551.27 million. DexCom sees FY2021 revenue of $2.35-2.4 billion, versus the consensus of $2.34 billion.</p>","source":"highlight_streetinsider","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>After-Hours Stock Movers: ERYTECH Pharma shares jumped 140%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAfter-Hours Stock Movers: ERYTECH Pharma shares jumped 140%\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-30 07:57 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.streetinsider.com/dr/news.php?id=18744154><strong>StreetInsider</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>After-Hours Stock Movers:\nERYTECH Pharma (Nasdaq: ERYP) 140% HIGHER; announced that the U.S. Food and Drug Administration (FDA) has granted eryaspase Fast Track designation for the treatment of acute ...</p>\n\n<a href=\"https://www.streetinsider.com/dr/news.php?id=18744154\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"DXCM":"德康医疗","TEAM":"Atlassian Corporation PLC","MSON":"Misonix Inc","SWKS":"思佳讯","ZYXI":"Zynex, Inc."},"source_url":"https://www.streetinsider.com/dr/news.php?id=18744154","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2155182860","content_text":"After-Hours Stock Movers:\nERYTECH Pharma (Nasdaq: ERYP) 140% HIGHER; announced that the U.S. Food and Drug Administration (FDA) has granted eryaspase Fast Track designation for the treatment of acute lymphocytic leukemia (ALL) patients who have developed hypersensitivity reactions to E. coli-derived pegylated asparaginase (PEG-ASNase).\nAtlassian (NASDAQ: TEAM) 13.2% HIGHER; reported Q4 EPS of $0.24, $0.06 better than the analyst estimate of $0.18. Revenue for the quarter came in at $560 million versus the consensus estimate of $524.09 million. Atlassian sees Q1 2022 EPS of $0.38-$0.39, versus the consensus of $0.31. Atlassian sees Q1 2022 revenue of $575-590 million, versus the consensus of $540.89 million.\nMisonix, Inc. (Nasdaq: MSON) 12% HIGHER; Bioventus Inc. (Nasdaq: BVS) (Bioventus), a global leader in innovations for active healing, and Misonix, Inc. (Nasdaq: MSON) (Misonix), a provider of minimally invasive therapeutic ultrasonic technologies and regenerative medicine that enhance clinical outcomes, today announced that they have entered into a definitive agreement by which Bioventus will acquire Misonix in a cash-and-stock transaction.\nZynex, Inc. (NASDAQ: ZYXI) 11% LOWER; reported Q2 EPS of $0.08, $0.02 better than the analyst estimate of $0.06. Revenue for the quarter came in at $31 million versus the consensus estimate of $31.31 million.\nZendesk (NYSE: ZEN) 7% LOWER; reported Q2 EPS of $0.13, $0.03 worse than the analyst estimate of $0.16. Revenue for the quarter came in at $318.2 million versus the consensus estimate of $319.79 million. Zendesk sees FY2021 revenue of $1.31-1.32 billion, versus the consensus of $1.31 billion. Zendesk sees Q3 2021 revenue of $332-337 billion, versus the consensus of $335.5 billion.\nSkyworks Solutions (NASDAQ: SWKS) 5.2% LOWER; reported Q3 EPS of $2.15, $0.01 better than the analyst estimate of $2.14. Revenue for the quarter came in at $1.12 billion versus the consensus estimate of $1.1 billion. Skyworks Solutions sees Q4 2021 EPS of $2.53-$2.48. Skyworks Solutions sees Q4 2021 revenue of $1.27-1.33 billion, versus the consensus of $1.22 billion.\nDexCom (NASDAQ: DXCM) 4.3% HIGHER; reported Q2 EPS of $0.76, $0.31 better than the analyst estimate of $0.45. Revenue for the quarter came in at $59.5 million versus the consensus estimate of $551.27 million. DexCom sees FY2021 revenue of $2.35-2.4 billion, versus the consensus of $2.34 billion.","news_type":1,"symbols_score_info":{"DXCM":0.9,"ERYP":0.9,"MSON":0.9,"SWKS":0.9,"TEAM":0.9,"ZEN":0.9,"ZYXI":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":806091327,"gmtCreate":1627614699269,"gmtModify":1631885715491,"author":{"id":"4088399516161040","authorId":"4088399516161040","name":"DKNY","avatar":"https://static.tigerbbs.com/e5359c87d0f8aa8acf397af5f2645463","vip":1,"crmLevel":3,"crmLevelSwitch":0,"idStr":"4088399516161040","authorIdStr":"4088399516161040"},"htmlText":"Good. Pls like.","listText":"Good. Pls like.","text":"Good. Pls like.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/806091327","repostId":2155182860,"repostType":4,"repost":{"id":"2155182860","kind":"news","pubTimestamp":1627603020,"share":"https://ttm.financial/m/news/2155182860?lang=&edition=full","pubTime":"2021-07-30 07:57","market":"us","language":"en","title":"After-Hours Stock Movers: ERYTECH Pharma shares jumped 140%","url":"https://stock-news.laohu8.com/highlight/detail?id=2155182860","media":"StreetInsider","summary":"After-Hours Stock Movers:\nERYTECH Pharma (Nasdaq: ERYP) 140% HIGHER; announced that the U.S. Food an","content":"<p>After-Hours Stock Movers:</p>\n<p>ERYTECH Pharma (Nasdaq: ERYP) 140% HIGHER; announced that the U.S. Food and Drug Administration (FDA) has granted eryaspase Fast Track designation for the treatment of acute lymphocytic leukemia (ALL) patients who have developed hypersensitivity reactions to E. coli-derived pegylated asparaginase (PEG-ASNase).</p>\n<p>Atlassian (NASDAQ: TEAM) 13.2% HIGHER; reported Q4 EPS of $0.24, $0.06 better than the analyst estimate of $0.18. Revenue for the quarter came in at $560 million versus the consensus estimate of $524.09 million. Atlassian sees Q1 2022 EPS of $0.38-$0.39, versus the consensus of $0.31. Atlassian sees Q1 2022 revenue of $575-590 million, versus the consensus of $540.89 million.</p>\n<p>Misonix, Inc. (Nasdaq: MSON) 12% HIGHER; <a href=\"https://laohu8.com/S/BIOV\">Bioventus Inc.</a> (Nasdaq: BVS) (Bioventus), a global leader in innovations for active healing, and Misonix, Inc. (Nasdaq: MSON) (Misonix), a provider of minimally invasive therapeutic ultrasonic technologies and regenerative medicine that enhance clinical outcomes, today announced that they have entered into a definitive agreement by which Bioventus will acquire Misonix in a cash-and-stock transaction.</p>\n<p><a href=\"https://laohu8.com/S/ZYXI\">Zynex, Inc.</a> (NASDAQ: ZYXI) 11% LOWER; reported Q2 EPS of $0.08, $0.02 better than the analyst estimate of $0.06. Revenue for the quarter came in at $31 million versus the consensus estimate of $31.31 million.</p>\n<p>Zendesk (NYSE: ZEN) 7% LOWER; reported Q2 EPS of $0.13, $0.03 worse than the analyst estimate of $0.16. Revenue for the quarter came in at $318.2 million versus the consensus estimate of $319.79 million. Zendesk sees FY2021 revenue of $1.31-1.32 billion, versus the consensus of $1.31 billion. Zendesk sees Q3 2021 revenue of $332-337 billion, versus the consensus of $335.5 billion.</p>\n<p>Skyworks Solutions (NASDAQ: SWKS) 5.2% LOWER; reported Q3 EPS of $2.15, $0.01 better than the analyst estimate of $2.14. Revenue for the quarter came in at $1.12 billion versus the consensus estimate of $1.1 billion. Skyworks Solutions sees Q4 2021 EPS of $2.53-$2.48. Skyworks Solutions sees Q4 2021 revenue of $1.27-1.33 billion, versus the consensus of $1.22 billion.</p>\n<p>DexCom (NASDAQ: DXCM) 4.3% HIGHER; reported Q2 EPS of $0.76, $0.31 better than the analyst estimate of $0.45. Revenue for the quarter came in at $59.5 million versus the consensus estimate of $551.27 million. DexCom sees FY2021 revenue of $2.35-2.4 billion, versus the consensus of $2.34 billion.</p>","source":"highlight_streetinsider","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>After-Hours Stock Movers: ERYTECH Pharma shares jumped 140%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAfter-Hours Stock Movers: ERYTECH Pharma shares jumped 140%\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-30 07:57 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.streetinsider.com/dr/news.php?id=18744154><strong>StreetInsider</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>After-Hours Stock Movers:\nERYTECH Pharma (Nasdaq: ERYP) 140% HIGHER; announced that the U.S. Food and Drug Administration (FDA) has granted eryaspase Fast Track designation for the treatment of acute ...</p>\n\n<a href=\"https://www.streetinsider.com/dr/news.php?id=18744154\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"DXCM":"德康医疗","TEAM":"Atlassian Corporation PLC","MSON":"Misonix Inc","SWKS":"思佳讯","ZYXI":"Zynex, Inc."},"source_url":"https://www.streetinsider.com/dr/news.php?id=18744154","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2155182860","content_text":"After-Hours Stock Movers:\nERYTECH Pharma (Nasdaq: ERYP) 140% HIGHER; announced that the U.S. Food and Drug Administration (FDA) has granted eryaspase Fast Track designation for the treatment of acute lymphocytic leukemia (ALL) patients who have developed hypersensitivity reactions to E. coli-derived pegylated asparaginase (PEG-ASNase).\nAtlassian (NASDAQ: TEAM) 13.2% HIGHER; reported Q4 EPS of $0.24, $0.06 better than the analyst estimate of $0.18. Revenue for the quarter came in at $560 million versus the consensus estimate of $524.09 million. Atlassian sees Q1 2022 EPS of $0.38-$0.39, versus the consensus of $0.31. Atlassian sees Q1 2022 revenue of $575-590 million, versus the consensus of $540.89 million.\nMisonix, Inc. (Nasdaq: MSON) 12% HIGHER; Bioventus Inc. (Nasdaq: BVS) (Bioventus), a global leader in innovations for active healing, and Misonix, Inc. (Nasdaq: MSON) (Misonix), a provider of minimally invasive therapeutic ultrasonic technologies and regenerative medicine that enhance clinical outcomes, today announced that they have entered into a definitive agreement by which Bioventus will acquire Misonix in a cash-and-stock transaction.\nZynex, Inc. (NASDAQ: ZYXI) 11% LOWER; reported Q2 EPS of $0.08, $0.02 better than the analyst estimate of $0.06. Revenue for the quarter came in at $31 million versus the consensus estimate of $31.31 million.\nZendesk (NYSE: ZEN) 7% LOWER; reported Q2 EPS of $0.13, $0.03 worse than the analyst estimate of $0.16. Revenue for the quarter came in at $318.2 million versus the consensus estimate of $319.79 million. Zendesk sees FY2021 revenue of $1.31-1.32 billion, versus the consensus of $1.31 billion. Zendesk sees Q3 2021 revenue of $332-337 billion, versus the consensus of $335.5 billion.\nSkyworks Solutions (NASDAQ: SWKS) 5.2% LOWER; reported Q3 EPS of $2.15, $0.01 better than the analyst estimate of $2.14. Revenue for the quarter came in at $1.12 billion versus the consensus estimate of $1.1 billion. Skyworks Solutions sees Q4 2021 EPS of $2.53-$2.48. Skyworks Solutions sees Q4 2021 revenue of $1.27-1.33 billion, versus the consensus of $1.22 billion.\nDexCom (NASDAQ: DXCM) 4.3% HIGHER; reported Q2 EPS of $0.76, $0.31 better than the analyst estimate of $0.45. Revenue for the quarter came in at $59.5 million versus the consensus estimate of $551.27 million. DexCom sees FY2021 revenue of $2.35-2.4 billion, versus the consensus of $2.34 billion.","news_type":1,"symbols_score_info":{"DXCM":0.9,"ERYP":0.9,"MSON":0.9,"SWKS":0.9,"TEAM":0.9,"ZEN":0.9,"ZYXI":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5376186,"gmtCreate":1627617979465,"gmtModify":1631885715499,"authorId":3574928367638029,"author":{"id":3574928367638029,"idStr":"3574928367638029","authorId":3574928367638029,"name":"kenong62","avatar":"https://static.tigerbbs.com/37fd00bd8cea11b8aa1aed6d9ddd9413","vip":1,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":806091327,"type":1,"supId":5375847,"prevId":0,"content":"done","text":"done","html":"done"},{"id":5375847,"gmtCreate":1627615511289,"gmtModify":1631885715490,"authorId":3573174299397007,"author":{"id":3573174299397007,"idStr":"3573174299397007","authorId":3573174299397007,"name":"Khairul0802","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":806091327,"type":1,"supId":0,"prevId":0,"content":"Ok","text":"Ok","html":"Ok"}],"langContent":"EN"},{"id":806007124,"gmtCreate":1627614458068,"gmtModify":1633757746133,"author":{"id":"3574924778363716","authorId":"3574924778363716","name":"sSS","avatar":"https://static.tigerbbs.com/6feafa4a828260badf8636e7a0776299","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3574924778363716","authorIdStr":"3574924778363716"},"htmlText":"Like pls","listText":"Like pls","text":"Like pls","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/806007124","repostId":2155182860,"repostType":4,"repost":{"id":"2155182860","kind":"news","pubTimestamp":1627603020,"share":"https://ttm.financial/m/news/2155182860?lang=&edition=full","pubTime":"2021-07-30 07:57","market":"us","language":"en","title":"After-Hours Stock Movers: ERYTECH Pharma shares jumped 140%","url":"https://stock-news.laohu8.com/highlight/detail?id=2155182860","media":"StreetInsider","summary":"After-Hours Stock Movers:\nERYTECH Pharma (Nasdaq: ERYP) 140% HIGHER; announced that the U.S. Food an","content":"<p>After-Hours Stock Movers:</p>\n<p>ERYTECH Pharma (Nasdaq: ERYP) 140% HIGHER; announced that the U.S. Food and Drug Administration (FDA) has granted eryaspase Fast Track designation for the treatment of acute lymphocytic leukemia (ALL) patients who have developed hypersensitivity reactions to E. coli-derived pegylated asparaginase (PEG-ASNase).</p>\n<p>Atlassian (NASDAQ: TEAM) 13.2% HIGHER; reported Q4 EPS of $0.24, $0.06 better than the analyst estimate of $0.18. Revenue for the quarter came in at $560 million versus the consensus estimate of $524.09 million. Atlassian sees Q1 2022 EPS of $0.38-$0.39, versus the consensus of $0.31. Atlassian sees Q1 2022 revenue of $575-590 million, versus the consensus of $540.89 million.</p>\n<p>Misonix, Inc. (Nasdaq: MSON) 12% HIGHER; <a href=\"https://laohu8.com/S/BIOV\">Bioventus Inc.</a> (Nasdaq: BVS) (Bioventus), a global leader in innovations for active healing, and Misonix, Inc. (Nasdaq: MSON) (Misonix), a provider of minimally invasive therapeutic ultrasonic technologies and regenerative medicine that enhance clinical outcomes, today announced that they have entered into a definitive agreement by which Bioventus will acquire Misonix in a cash-and-stock transaction.</p>\n<p><a href=\"https://laohu8.com/S/ZYXI\">Zynex, Inc.</a> (NASDAQ: ZYXI) 11% LOWER; reported Q2 EPS of $0.08, $0.02 better than the analyst estimate of $0.06. Revenue for the quarter came in at $31 million versus the consensus estimate of $31.31 million.</p>\n<p>Zendesk (NYSE: ZEN) 7% LOWER; reported Q2 EPS of $0.13, $0.03 worse than the analyst estimate of $0.16. Revenue for the quarter came in at $318.2 million versus the consensus estimate of $319.79 million. Zendesk sees FY2021 revenue of $1.31-1.32 billion, versus the consensus of $1.31 billion. Zendesk sees Q3 2021 revenue of $332-337 billion, versus the consensus of $335.5 billion.</p>\n<p>Skyworks Solutions (NASDAQ: SWKS) 5.2% LOWER; reported Q3 EPS of $2.15, $0.01 better than the analyst estimate of $2.14. Revenue for the quarter came in at $1.12 billion versus the consensus estimate of $1.1 billion. Skyworks Solutions sees Q4 2021 EPS of $2.53-$2.48. Skyworks Solutions sees Q4 2021 revenue of $1.27-1.33 billion, versus the consensus of $1.22 billion.</p>\n<p>DexCom (NASDAQ: DXCM) 4.3% HIGHER; reported Q2 EPS of $0.76, $0.31 better than the analyst estimate of $0.45. Revenue for the quarter came in at $59.5 million versus the consensus estimate of $551.27 million. DexCom sees FY2021 revenue of $2.35-2.4 billion, versus the consensus of $2.34 billion.</p>","source":"highlight_streetinsider","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>After-Hours Stock Movers: ERYTECH Pharma shares jumped 140%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAfter-Hours Stock Movers: ERYTECH Pharma shares jumped 140%\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-30 07:57 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.streetinsider.com/dr/news.php?id=18744154><strong>StreetInsider</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>After-Hours Stock Movers:\nERYTECH Pharma (Nasdaq: ERYP) 140% HIGHER; announced that the U.S. Food and Drug Administration (FDA) has granted eryaspase Fast Track designation for the treatment of acute ...</p>\n\n<a href=\"https://www.streetinsider.com/dr/news.php?id=18744154\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"DXCM":"德康医疗","TEAM":"Atlassian Corporation PLC","MSON":"Misonix Inc","SWKS":"思佳讯","ZYXI":"Zynex, Inc."},"source_url":"https://www.streetinsider.com/dr/news.php?id=18744154","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2155182860","content_text":"After-Hours Stock Movers:\nERYTECH Pharma (Nasdaq: ERYP) 140% HIGHER; announced that the U.S. Food and Drug Administration (FDA) has granted eryaspase Fast Track designation for the treatment of acute lymphocytic leukemia (ALL) patients who have developed hypersensitivity reactions to E. coli-derived pegylated asparaginase (PEG-ASNase).\nAtlassian (NASDAQ: TEAM) 13.2% HIGHER; reported Q4 EPS of $0.24, $0.06 better than the analyst estimate of $0.18. Revenue for the quarter came in at $560 million versus the consensus estimate of $524.09 million. Atlassian sees Q1 2022 EPS of $0.38-$0.39, versus the consensus of $0.31. Atlassian sees Q1 2022 revenue of $575-590 million, versus the consensus of $540.89 million.\nMisonix, Inc. (Nasdaq: MSON) 12% HIGHER; Bioventus Inc. (Nasdaq: BVS) (Bioventus), a global leader in innovations for active healing, and Misonix, Inc. (Nasdaq: MSON) (Misonix), a provider of minimally invasive therapeutic ultrasonic technologies and regenerative medicine that enhance clinical outcomes, today announced that they have entered into a definitive agreement by which Bioventus will acquire Misonix in a cash-and-stock transaction.\nZynex, Inc. (NASDAQ: ZYXI) 11% LOWER; reported Q2 EPS of $0.08, $0.02 better than the analyst estimate of $0.06. Revenue for the quarter came in at $31 million versus the consensus estimate of $31.31 million.\nZendesk (NYSE: ZEN) 7% LOWER; reported Q2 EPS of $0.13, $0.03 worse than the analyst estimate of $0.16. Revenue for the quarter came in at $318.2 million versus the consensus estimate of $319.79 million. Zendesk sees FY2021 revenue of $1.31-1.32 billion, versus the consensus of $1.31 billion. Zendesk sees Q3 2021 revenue of $332-337 billion, versus the consensus of $335.5 billion.\nSkyworks Solutions (NASDAQ: SWKS) 5.2% LOWER; reported Q3 EPS of $2.15, $0.01 better than the analyst estimate of $2.14. Revenue for the quarter came in at $1.12 billion versus the consensus estimate of $1.1 billion. Skyworks Solutions sees Q4 2021 EPS of $2.53-$2.48. Skyworks Solutions sees Q4 2021 revenue of $1.27-1.33 billion, versus the consensus of $1.22 billion.\nDexCom (NASDAQ: DXCM) 4.3% HIGHER; reported Q2 EPS of $0.76, $0.31 better than the analyst estimate of $0.45. Revenue for the quarter came in at $59.5 million versus the consensus estimate of $551.27 million. DexCom sees FY2021 revenue of $2.35-2.4 billion, versus the consensus of $2.34 billion.","news_type":1,"symbols_score_info":{"DXCM":0.9,"ERYP":0.9,"MSON":0.9,"SWKS":0.9,"TEAM":0.9,"ZEN":0.9,"ZYXI":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":806009969,"gmtCreate":1627613900151,"gmtModify":1633757752475,"author":{"id":"4087685930931350","authorId":"4087685930931350","name":"Upswing118","avatar":"https://static.tigerbbs.com/5ee810deeb4fd3c3d863b49cef1d9956","vip":1,"crmLevel":5,"crmLevelSwitch":0,"idStr":"4087685930931350","authorIdStr":"4087685930931350"},"htmlText":"How nice if the same happened to china based stocks[得意]&nbsp;","listText":"How nice if the same happened to china based stocks[得意]&nbsp;","text":"How nice if the same happened to china based stocks[得意]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/806009969","repostId":2155182860,"repostType":4,"repost":{"id":"2155182860","kind":"news","pubTimestamp":1627603020,"share":"https://ttm.financial/m/news/2155182860?lang=&edition=full","pubTime":"2021-07-30 07:57","market":"us","language":"en","title":"After-Hours Stock Movers: ERYTECH Pharma shares jumped 140%","url":"https://stock-news.laohu8.com/highlight/detail?id=2155182860","media":"StreetInsider","summary":"After-Hours Stock Movers:\nERYTECH Pharma (Nasdaq: ERYP) 140% HIGHER; announced that the U.S. Food an","content":"<p>After-Hours Stock Movers:</p>\n<p>ERYTECH Pharma (Nasdaq: ERYP) 140% HIGHER; announced that the U.S. Food and Drug Administration (FDA) has granted eryaspase Fast Track designation for the treatment of acute lymphocytic leukemia (ALL) patients who have developed hypersensitivity reactions to E. coli-derived pegylated asparaginase (PEG-ASNase).</p>\n<p>Atlassian (NASDAQ: TEAM) 13.2% HIGHER; reported Q4 EPS of $0.24, $0.06 better than the analyst estimate of $0.18. Revenue for the quarter came in at $560 million versus the consensus estimate of $524.09 million. Atlassian sees Q1 2022 EPS of $0.38-$0.39, versus the consensus of $0.31. Atlassian sees Q1 2022 revenue of $575-590 million, versus the consensus of $540.89 million.</p>\n<p>Misonix, Inc. (Nasdaq: MSON) 12% HIGHER; <a href=\"https://laohu8.com/S/BIOV\">Bioventus Inc.</a> (Nasdaq: BVS) (Bioventus), a global leader in innovations for active healing, and Misonix, Inc. (Nasdaq: MSON) (Misonix), a provider of minimally invasive therapeutic ultrasonic technologies and regenerative medicine that enhance clinical outcomes, today announced that they have entered into a definitive agreement by which Bioventus will acquire Misonix in a cash-and-stock transaction.</p>\n<p><a href=\"https://laohu8.com/S/ZYXI\">Zynex, Inc.</a> (NASDAQ: ZYXI) 11% LOWER; reported Q2 EPS of $0.08, $0.02 better than the analyst estimate of $0.06. Revenue for the quarter came in at $31 million versus the consensus estimate of $31.31 million.</p>\n<p>Zendesk (NYSE: ZEN) 7% LOWER; reported Q2 EPS of $0.13, $0.03 worse than the analyst estimate of $0.16. Revenue for the quarter came in at $318.2 million versus the consensus estimate of $319.79 million. Zendesk sees FY2021 revenue of $1.31-1.32 billion, versus the consensus of $1.31 billion. Zendesk sees Q3 2021 revenue of $332-337 billion, versus the consensus of $335.5 billion.</p>\n<p>Skyworks Solutions (NASDAQ: SWKS) 5.2% LOWER; reported Q3 EPS of $2.15, $0.01 better than the analyst estimate of $2.14. Revenue for the quarter came in at $1.12 billion versus the consensus estimate of $1.1 billion. Skyworks Solutions sees Q4 2021 EPS of $2.53-$2.48. Skyworks Solutions sees Q4 2021 revenue of $1.27-1.33 billion, versus the consensus of $1.22 billion.</p>\n<p>DexCom (NASDAQ: DXCM) 4.3% HIGHER; reported Q2 EPS of $0.76, $0.31 better than the analyst estimate of $0.45. Revenue for the quarter came in at $59.5 million versus the consensus estimate of $551.27 million. DexCom sees FY2021 revenue of $2.35-2.4 billion, versus the consensus of $2.34 billion.</p>","source":"highlight_streetinsider","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>After-Hours Stock Movers: ERYTECH Pharma shares jumped 140%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAfter-Hours Stock Movers: ERYTECH Pharma shares jumped 140%\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-30 07:57 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.streetinsider.com/dr/news.php?id=18744154><strong>StreetInsider</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>After-Hours Stock Movers:\nERYTECH Pharma (Nasdaq: ERYP) 140% HIGHER; announced that the U.S. Food and Drug Administration (FDA) has granted eryaspase Fast Track designation for the treatment of acute ...</p>\n\n<a href=\"https://www.streetinsider.com/dr/news.php?id=18744154\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"DXCM":"德康医疗","TEAM":"Atlassian Corporation PLC","MSON":"Misonix Inc","SWKS":"思佳讯","ZYXI":"Zynex, Inc."},"source_url":"https://www.streetinsider.com/dr/news.php?id=18744154","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2155182860","content_text":"After-Hours Stock Movers:\nERYTECH Pharma (Nasdaq: ERYP) 140% HIGHER; announced that the U.S. Food and Drug Administration (FDA) has granted eryaspase Fast Track designation for the treatment of acute lymphocytic leukemia (ALL) patients who have developed hypersensitivity reactions to E. coli-derived pegylated asparaginase (PEG-ASNase).\nAtlassian (NASDAQ: TEAM) 13.2% HIGHER; reported Q4 EPS of $0.24, $0.06 better than the analyst estimate of $0.18. Revenue for the quarter came in at $560 million versus the consensus estimate of $524.09 million. Atlassian sees Q1 2022 EPS of $0.38-$0.39, versus the consensus of $0.31. Atlassian sees Q1 2022 revenue of $575-590 million, versus the consensus of $540.89 million.\nMisonix, Inc. (Nasdaq: MSON) 12% HIGHER; Bioventus Inc. (Nasdaq: BVS) (Bioventus), a global leader in innovations for active healing, and Misonix, Inc. (Nasdaq: MSON) (Misonix), a provider of minimally invasive therapeutic ultrasonic technologies and regenerative medicine that enhance clinical outcomes, today announced that they have entered into a definitive agreement by which Bioventus will acquire Misonix in a cash-and-stock transaction.\nZynex, Inc. (NASDAQ: ZYXI) 11% LOWER; reported Q2 EPS of $0.08, $0.02 better than the analyst estimate of $0.06. Revenue for the quarter came in at $31 million versus the consensus estimate of $31.31 million.\nZendesk (NYSE: ZEN) 7% LOWER; reported Q2 EPS of $0.13, $0.03 worse than the analyst estimate of $0.16. Revenue for the quarter came in at $318.2 million versus the consensus estimate of $319.79 million. Zendesk sees FY2021 revenue of $1.31-1.32 billion, versus the consensus of $1.31 billion. Zendesk sees Q3 2021 revenue of $332-337 billion, versus the consensus of $335.5 billion.\nSkyworks Solutions (NASDAQ: SWKS) 5.2% LOWER; reported Q3 EPS of $2.15, $0.01 better than the analyst estimate of $2.14. Revenue for the quarter came in at $1.12 billion versus the consensus estimate of $1.1 billion. Skyworks Solutions sees Q4 2021 EPS of $2.53-$2.48. Skyworks Solutions sees Q4 2021 revenue of $1.27-1.33 billion, versus the consensus of $1.22 billion.\nDexCom (NASDAQ: DXCM) 4.3% HIGHER; reported Q2 EPS of $0.76, $0.31 better than the analyst estimate of $0.45. Revenue for the quarter came in at $59.5 million versus the consensus estimate of $551.27 million. DexCom sees FY2021 revenue of $2.35-2.4 billion, versus the consensus of $2.34 billion.","news_type":1,"symbols_score_info":{"DXCM":0.9,"ERYP":0.9,"MSON":0.9,"SWKS":0.9,"TEAM":0.9,"ZEN":0.9,"ZYXI":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"},{"id":808771945,"gmtCreate":1627613406587,"gmtModify":1633757758237,"author":{"id":"3561677110311504","authorId":"3561677110311504","name":"Mr小白","avatar":"https://static.tigerbbs.com/6254bbf8c65e8c668db8db59c22ae5d7","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3561677110311504","authorIdStr":"3561677110311504"},"htmlText":"Ohhh","listText":"Ohhh","text":"Ohhh","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/808771945","repostId":2155182860,"repostType":4,"repost":{"id":"2155182860","kind":"news","pubTimestamp":1627603020,"share":"https://ttm.financial/m/news/2155182860?lang=&edition=full","pubTime":"2021-07-30 07:57","market":"us","language":"en","title":"After-Hours Stock Movers: ERYTECH Pharma shares jumped 140%","url":"https://stock-news.laohu8.com/highlight/detail?id=2155182860","media":"StreetInsider","summary":"After-Hours Stock Movers:\nERYTECH Pharma (Nasdaq: ERYP) 140% HIGHER; announced that the U.S. Food an","content":"<p>After-Hours Stock Movers:</p>\n<p>ERYTECH Pharma (Nasdaq: ERYP) 140% HIGHER; announced that the U.S. Food and Drug Administration (FDA) has granted eryaspase Fast Track designation for the treatment of acute lymphocytic leukemia (ALL) patients who have developed hypersensitivity reactions to E. coli-derived pegylated asparaginase (PEG-ASNase).</p>\n<p>Atlassian (NASDAQ: TEAM) 13.2% HIGHER; reported Q4 EPS of $0.24, $0.06 better than the analyst estimate of $0.18. Revenue for the quarter came in at $560 million versus the consensus estimate of $524.09 million. Atlassian sees Q1 2022 EPS of $0.38-$0.39, versus the consensus of $0.31. Atlassian sees Q1 2022 revenue of $575-590 million, versus the consensus of $540.89 million.</p>\n<p>Misonix, Inc. (Nasdaq: MSON) 12% HIGHER; <a href=\"https://laohu8.com/S/BIOV\">Bioventus Inc.</a> (Nasdaq: BVS) (Bioventus), a global leader in innovations for active healing, and Misonix, Inc. (Nasdaq: MSON) (Misonix), a provider of minimally invasive therapeutic ultrasonic technologies and regenerative medicine that enhance clinical outcomes, today announced that they have entered into a definitive agreement by which Bioventus will acquire Misonix in a cash-and-stock transaction.</p>\n<p><a href=\"https://laohu8.com/S/ZYXI\">Zynex, Inc.</a> (NASDAQ: ZYXI) 11% LOWER; reported Q2 EPS of $0.08, $0.02 better than the analyst estimate of $0.06. Revenue for the quarter came in at $31 million versus the consensus estimate of $31.31 million.</p>\n<p>Zendesk (NYSE: ZEN) 7% LOWER; reported Q2 EPS of $0.13, $0.03 worse than the analyst estimate of $0.16. Revenue for the quarter came in at $318.2 million versus the consensus estimate of $319.79 million. Zendesk sees FY2021 revenue of $1.31-1.32 billion, versus the consensus of $1.31 billion. Zendesk sees Q3 2021 revenue of $332-337 billion, versus the consensus of $335.5 billion.</p>\n<p>Skyworks Solutions (NASDAQ: SWKS) 5.2% LOWER; reported Q3 EPS of $2.15, $0.01 better than the analyst estimate of $2.14. Revenue for the quarter came in at $1.12 billion versus the consensus estimate of $1.1 billion. Skyworks Solutions sees Q4 2021 EPS of $2.53-$2.48. Skyworks Solutions sees Q4 2021 revenue of $1.27-1.33 billion, versus the consensus of $1.22 billion.</p>\n<p>DexCom (NASDAQ: DXCM) 4.3% HIGHER; reported Q2 EPS of $0.76, $0.31 better than the analyst estimate of $0.45. Revenue for the quarter came in at $59.5 million versus the consensus estimate of $551.27 million. DexCom sees FY2021 revenue of $2.35-2.4 billion, versus the consensus of $2.34 billion.</p>","source":"highlight_streetinsider","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>After-Hours Stock Movers: ERYTECH Pharma shares jumped 140%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAfter-Hours Stock Movers: ERYTECH Pharma shares jumped 140%\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-30 07:57 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.streetinsider.com/dr/news.php?id=18744154><strong>StreetInsider</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>After-Hours Stock Movers:\nERYTECH Pharma (Nasdaq: ERYP) 140% HIGHER; announced that the U.S. Food and Drug Administration (FDA) has granted eryaspase Fast Track designation for the treatment of acute ...</p>\n\n<a href=\"https://www.streetinsider.com/dr/news.php?id=18744154\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"DXCM":"德康医疗","TEAM":"Atlassian Corporation PLC","MSON":"Misonix Inc","SWKS":"思佳讯","ZYXI":"Zynex, Inc."},"source_url":"https://www.streetinsider.com/dr/news.php?id=18744154","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2155182860","content_text":"After-Hours Stock Movers:\nERYTECH Pharma (Nasdaq: ERYP) 140% HIGHER; announced that the U.S. Food and Drug Administration (FDA) has granted eryaspase Fast Track designation for the treatment of acute lymphocytic leukemia (ALL) patients who have developed hypersensitivity reactions to E. coli-derived pegylated asparaginase (PEG-ASNase).\nAtlassian (NASDAQ: TEAM) 13.2% HIGHER; reported Q4 EPS of $0.24, $0.06 better than the analyst estimate of $0.18. Revenue for the quarter came in at $560 million versus the consensus estimate of $524.09 million. Atlassian sees Q1 2022 EPS of $0.38-$0.39, versus the consensus of $0.31. Atlassian sees Q1 2022 revenue of $575-590 million, versus the consensus of $540.89 million.\nMisonix, Inc. (Nasdaq: MSON) 12% HIGHER; Bioventus Inc. (Nasdaq: BVS) (Bioventus), a global leader in innovations for active healing, and Misonix, Inc. (Nasdaq: MSON) (Misonix), a provider of minimally invasive therapeutic ultrasonic technologies and regenerative medicine that enhance clinical outcomes, today announced that they have entered into a definitive agreement by which Bioventus will acquire Misonix in a cash-and-stock transaction.\nZynex, Inc. (NASDAQ: ZYXI) 11% LOWER; reported Q2 EPS of $0.08, $0.02 better than the analyst estimate of $0.06. Revenue for the quarter came in at $31 million versus the consensus estimate of $31.31 million.\nZendesk (NYSE: ZEN) 7% LOWER; reported Q2 EPS of $0.13, $0.03 worse than the analyst estimate of $0.16. Revenue for the quarter came in at $318.2 million versus the consensus estimate of $319.79 million. Zendesk sees FY2021 revenue of $1.31-1.32 billion, versus the consensus of $1.31 billion. Zendesk sees Q3 2021 revenue of $332-337 billion, versus the consensus of $335.5 billion.\nSkyworks Solutions (NASDAQ: SWKS) 5.2% LOWER; reported Q3 EPS of $2.15, $0.01 better than the analyst estimate of $2.14. Revenue for the quarter came in at $1.12 billion versus the consensus estimate of $1.1 billion. Skyworks Solutions sees Q4 2021 EPS of $2.53-$2.48. Skyworks Solutions sees Q4 2021 revenue of $1.27-1.33 billion, versus the consensus of $1.22 billion.\nDexCom (NASDAQ: DXCM) 4.3% HIGHER; reported Q2 EPS of $0.76, $0.31 better than the analyst estimate of $0.45. Revenue for the quarter came in at $59.5 million versus the consensus estimate of $551.27 million. DexCom sees FY2021 revenue of $2.35-2.4 billion, versus the consensus of $2.34 billion.","news_type":1,"symbols_score_info":{"DXCM":0.9,"ERYP":0.9,"MSON":0.9,"SWKS":0.9,"TEAM":0.9,"ZEN":0.9,"ZYXI":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":808727812,"gmtCreate":1627611892736,"gmtModify":1633757774968,"author":{"id":"3583719080393906","authorId":"3583719080393906","name":"PREM","avatar":"https://static.tigerbbs.com/bd4e9099a744c8af75ebaa2e0ce2f09b","vip":1,"crmLevel":3,"crmLevelSwitch":0,"idStr":"3583719080393906","authorIdStr":"3583719080393906"},"htmlText":"Most reliable stocks&nbsp;","listText":"Most reliable stocks&nbsp;","text":"Most reliable stocks","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/808727812","repostId":2155182860,"repostType":4,"repost":{"id":"2155182860","kind":"news","pubTimestamp":1627603020,"share":"https://ttm.financial/m/news/2155182860?lang=&edition=full","pubTime":"2021-07-30 07:57","market":"us","language":"en","title":"After-Hours Stock Movers: ERYTECH Pharma shares jumped 140%","url":"https://stock-news.laohu8.com/highlight/detail?id=2155182860","media":"StreetInsider","summary":"After-Hours Stock Movers:\nERYTECH Pharma (Nasdaq: ERYP) 140% HIGHER; announced that the U.S. Food an","content":"<p>After-Hours Stock Movers:</p>\n<p>ERYTECH Pharma (Nasdaq: ERYP) 140% HIGHER; announced that the U.S. Food and Drug Administration (FDA) has granted eryaspase Fast Track designation for the treatment of acute lymphocytic leukemia (ALL) patients who have developed hypersensitivity reactions to E. coli-derived pegylated asparaginase (PEG-ASNase).</p>\n<p>Atlassian (NASDAQ: TEAM) 13.2% HIGHER; reported Q4 EPS of $0.24, $0.06 better than the analyst estimate of $0.18. Revenue for the quarter came in at $560 million versus the consensus estimate of $524.09 million. Atlassian sees Q1 2022 EPS of $0.38-$0.39, versus the consensus of $0.31. Atlassian sees Q1 2022 revenue of $575-590 million, versus the consensus of $540.89 million.</p>\n<p>Misonix, Inc. (Nasdaq: MSON) 12% HIGHER; <a href=\"https://laohu8.com/S/BIOV\">Bioventus Inc.</a> (Nasdaq: BVS) (Bioventus), a global leader in innovations for active healing, and Misonix, Inc. (Nasdaq: MSON) (Misonix), a provider of minimally invasive therapeutic ultrasonic technologies and regenerative medicine that enhance clinical outcomes, today announced that they have entered into a definitive agreement by which Bioventus will acquire Misonix in a cash-and-stock transaction.</p>\n<p><a href=\"https://laohu8.com/S/ZYXI\">Zynex, Inc.</a> (NASDAQ: ZYXI) 11% LOWER; reported Q2 EPS of $0.08, $0.02 better than the analyst estimate of $0.06. Revenue for the quarter came in at $31 million versus the consensus estimate of $31.31 million.</p>\n<p>Zendesk (NYSE: ZEN) 7% LOWER; reported Q2 EPS of $0.13, $0.03 worse than the analyst estimate of $0.16. Revenue for the quarter came in at $318.2 million versus the consensus estimate of $319.79 million. Zendesk sees FY2021 revenue of $1.31-1.32 billion, versus the consensus of $1.31 billion. Zendesk sees Q3 2021 revenue of $332-337 billion, versus the consensus of $335.5 billion.</p>\n<p>Skyworks Solutions (NASDAQ: SWKS) 5.2% LOWER; reported Q3 EPS of $2.15, $0.01 better than the analyst estimate of $2.14. Revenue for the quarter came in at $1.12 billion versus the consensus estimate of $1.1 billion. Skyworks Solutions sees Q4 2021 EPS of $2.53-$2.48. Skyworks Solutions sees Q4 2021 revenue of $1.27-1.33 billion, versus the consensus of $1.22 billion.</p>\n<p>DexCom (NASDAQ: DXCM) 4.3% HIGHER; reported Q2 EPS of $0.76, $0.31 better than the analyst estimate of $0.45. Revenue for the quarter came in at $59.5 million versus the consensus estimate of $551.27 million. DexCom sees FY2021 revenue of $2.35-2.4 billion, versus the consensus of $2.34 billion.</p>","source":"highlight_streetinsider","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>After-Hours Stock Movers: ERYTECH Pharma shares jumped 140%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAfter-Hours Stock Movers: ERYTECH Pharma shares jumped 140%\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-30 07:57 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.streetinsider.com/dr/news.php?id=18744154><strong>StreetInsider</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>After-Hours Stock Movers:\nERYTECH Pharma (Nasdaq: ERYP) 140% HIGHER; announced that the U.S. Food and Drug Administration (FDA) has granted eryaspase Fast Track designation for the treatment of acute ...</p>\n\n<a href=\"https://www.streetinsider.com/dr/news.php?id=18744154\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"DXCM":"德康医疗","TEAM":"Atlassian Corporation PLC","MSON":"Misonix Inc","SWKS":"思佳讯","ZYXI":"Zynex, Inc."},"source_url":"https://www.streetinsider.com/dr/news.php?id=18744154","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2155182860","content_text":"After-Hours Stock Movers:\nERYTECH Pharma (Nasdaq: ERYP) 140% HIGHER; announced that the U.S. Food and Drug Administration (FDA) has granted eryaspase Fast Track designation for the treatment of acute lymphocytic leukemia (ALL) patients who have developed hypersensitivity reactions to E. coli-derived pegylated asparaginase (PEG-ASNase).\nAtlassian (NASDAQ: TEAM) 13.2% HIGHER; reported Q4 EPS of $0.24, $0.06 better than the analyst estimate of $0.18. Revenue for the quarter came in at $560 million versus the consensus estimate of $524.09 million. Atlassian sees Q1 2022 EPS of $0.38-$0.39, versus the consensus of $0.31. Atlassian sees Q1 2022 revenue of $575-590 million, versus the consensus of $540.89 million.\nMisonix, Inc. (Nasdaq: MSON) 12% HIGHER; Bioventus Inc. (Nasdaq: BVS) (Bioventus), a global leader in innovations for active healing, and Misonix, Inc. (Nasdaq: MSON) (Misonix), a provider of minimally invasive therapeutic ultrasonic technologies and regenerative medicine that enhance clinical outcomes, today announced that they have entered into a definitive agreement by which Bioventus will acquire Misonix in a cash-and-stock transaction.\nZynex, Inc. (NASDAQ: ZYXI) 11% LOWER; reported Q2 EPS of $0.08, $0.02 better than the analyst estimate of $0.06. Revenue for the quarter came in at $31 million versus the consensus estimate of $31.31 million.\nZendesk (NYSE: ZEN) 7% LOWER; reported Q2 EPS of $0.13, $0.03 worse than the analyst estimate of $0.16. Revenue for the quarter came in at $318.2 million versus the consensus estimate of $319.79 million. Zendesk sees FY2021 revenue of $1.31-1.32 billion, versus the consensus of $1.31 billion. Zendesk sees Q3 2021 revenue of $332-337 billion, versus the consensus of $335.5 billion.\nSkyworks Solutions (NASDAQ: SWKS) 5.2% LOWER; reported Q3 EPS of $2.15, $0.01 better than the analyst estimate of $2.14. Revenue for the quarter came in at $1.12 billion versus the consensus estimate of $1.1 billion. Skyworks Solutions sees Q4 2021 EPS of $2.53-$2.48. Skyworks Solutions sees Q4 2021 revenue of $1.27-1.33 billion, versus the consensus of $1.22 billion.\nDexCom (NASDAQ: DXCM) 4.3% HIGHER; reported Q2 EPS of $0.76, $0.31 better than the analyst estimate of $0.45. Revenue for the quarter came in at $59.5 million versus the consensus estimate of $551.27 million. DexCom sees FY2021 revenue of $2.35-2.4 billion, versus the consensus of $2.34 billion.","news_type":1,"symbols_score_info":{"DXCM":0.9,"ERYP":0.9,"MSON":0.9,"SWKS":0.9,"TEAM":0.9,"ZEN":0.9,"ZYXI":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5375486,"gmtCreate":1627612343047,"gmtModify":1635164422060,"authorId":4087454422417330,"author":{"id":4087454422417330,"idStr":"4087454422417330","authorId":4087454422417330,"name":"junan","avatar":"https://static.tigerbbs.com/01c6bbe9bc1c46918924830458fea61c","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":808727812,"type":1,"supId":0,"prevId":0,"content":"Yup","text":"Yup","html":"Yup"}],"langContent":"EN"},{"id":808718835,"gmtCreate":1627610154227,"gmtModify":1633757801453,"author":{"id":"3570689023160998","authorId":"3570689023160998","name":"您解释看看","avatar":"https://static.tigerbbs.com/534b01f4d9f64217e12e115de2fef0e1","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3570689023160998","authorIdStr":"3570689023160998"},"htmlText":"[Miser]&nbsp;[Miser]&nbsp;","listText":"[Miser]&nbsp;[Miser]&nbsp;","text":"[Miser] [Miser]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/808718835","repostId":2155182860,"repostType":4,"repost":{"id":"2155182860","kind":"news","pubTimestamp":1627603020,"share":"https://ttm.financial/m/news/2155182860?lang=&edition=full","pubTime":"2021-07-30 07:57","market":"us","language":"en","title":"After-Hours Stock Movers: ERYTECH Pharma shares jumped 140%","url":"https://stock-news.laohu8.com/highlight/detail?id=2155182860","media":"StreetInsider","summary":"After-Hours Stock Movers:\nERYTECH Pharma (Nasdaq: ERYP) 140% HIGHER; announced that the U.S. Food an","content":"<p>After-Hours Stock Movers:</p>\n<p>ERYTECH Pharma (Nasdaq: ERYP) 140% HIGHER; announced that the U.S. Food and Drug Administration (FDA) has granted eryaspase Fast Track designation for the treatment of acute lymphocytic leukemia (ALL) patients who have developed hypersensitivity reactions to E. coli-derived pegylated asparaginase (PEG-ASNase).</p>\n<p>Atlassian (NASDAQ: TEAM) 13.2% HIGHER; reported Q4 EPS of $0.24, $0.06 better than the analyst estimate of $0.18. Revenue for the quarter came in at $560 million versus the consensus estimate of $524.09 million. Atlassian sees Q1 2022 EPS of $0.38-$0.39, versus the consensus of $0.31. Atlassian sees Q1 2022 revenue of $575-590 million, versus the consensus of $540.89 million.</p>\n<p>Misonix, Inc. (Nasdaq: MSON) 12% HIGHER; <a href=\"https://laohu8.com/S/BIOV\">Bioventus Inc.</a> (Nasdaq: BVS) (Bioventus), a global leader in innovations for active healing, and Misonix, Inc. (Nasdaq: MSON) (Misonix), a provider of minimally invasive therapeutic ultrasonic technologies and regenerative medicine that enhance clinical outcomes, today announced that they have entered into a definitive agreement by which Bioventus will acquire Misonix in a cash-and-stock transaction.</p>\n<p><a href=\"https://laohu8.com/S/ZYXI\">Zynex, Inc.</a> (NASDAQ: ZYXI) 11% LOWER; reported Q2 EPS of $0.08, $0.02 better than the analyst estimate of $0.06. Revenue for the quarter came in at $31 million versus the consensus estimate of $31.31 million.</p>\n<p>Zendesk (NYSE: ZEN) 7% LOWER; reported Q2 EPS of $0.13, $0.03 worse than the analyst estimate of $0.16. Revenue for the quarter came in at $318.2 million versus the consensus estimate of $319.79 million. Zendesk sees FY2021 revenue of $1.31-1.32 billion, versus the consensus of $1.31 billion. Zendesk sees Q3 2021 revenue of $332-337 billion, versus the consensus of $335.5 billion.</p>\n<p>Skyworks Solutions (NASDAQ: SWKS) 5.2% LOWER; reported Q3 EPS of $2.15, $0.01 better than the analyst estimate of $2.14. Revenue for the quarter came in at $1.12 billion versus the consensus estimate of $1.1 billion. Skyworks Solutions sees Q4 2021 EPS of $2.53-$2.48. Skyworks Solutions sees Q4 2021 revenue of $1.27-1.33 billion, versus the consensus of $1.22 billion.</p>\n<p>DexCom (NASDAQ: DXCM) 4.3% HIGHER; reported Q2 EPS of $0.76, $0.31 better than the analyst estimate of $0.45. Revenue for the quarter came in at $59.5 million versus the consensus estimate of $551.27 million. DexCom sees FY2021 revenue of $2.35-2.4 billion, versus the consensus of $2.34 billion.</p>","source":"highlight_streetinsider","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>After-Hours Stock Movers: ERYTECH Pharma shares jumped 140%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAfter-Hours Stock Movers: ERYTECH Pharma shares jumped 140%\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-30 07:57 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.streetinsider.com/dr/news.php?id=18744154><strong>StreetInsider</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>After-Hours Stock Movers:\nERYTECH Pharma (Nasdaq: ERYP) 140% HIGHER; announced that the U.S. Food and Drug Administration (FDA) has granted eryaspase Fast Track designation for the treatment of acute ...</p>\n\n<a href=\"https://www.streetinsider.com/dr/news.php?id=18744154\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"DXCM":"德康医疗","TEAM":"Atlassian Corporation PLC","MSON":"Misonix Inc","SWKS":"思佳讯","ZYXI":"Zynex, Inc."},"source_url":"https://www.streetinsider.com/dr/news.php?id=18744154","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2155182860","content_text":"After-Hours Stock Movers:\nERYTECH Pharma (Nasdaq: ERYP) 140% HIGHER; announced that the U.S. Food and Drug Administration (FDA) has granted eryaspase Fast Track designation for the treatment of acute lymphocytic leukemia (ALL) patients who have developed hypersensitivity reactions to E. coli-derived pegylated asparaginase (PEG-ASNase).\nAtlassian (NASDAQ: TEAM) 13.2% HIGHER; reported Q4 EPS of $0.24, $0.06 better than the analyst estimate of $0.18. Revenue for the quarter came in at $560 million versus the consensus estimate of $524.09 million. Atlassian sees Q1 2022 EPS of $0.38-$0.39, versus the consensus of $0.31. Atlassian sees Q1 2022 revenue of $575-590 million, versus the consensus of $540.89 million.\nMisonix, Inc. (Nasdaq: MSON) 12% HIGHER; Bioventus Inc. (Nasdaq: BVS) (Bioventus), a global leader in innovations for active healing, and Misonix, Inc. (Nasdaq: MSON) (Misonix), a provider of minimally invasive therapeutic ultrasonic technologies and regenerative medicine that enhance clinical outcomes, today announced that they have entered into a definitive agreement by which Bioventus will acquire Misonix in a cash-and-stock transaction.\nZynex, Inc. (NASDAQ: ZYXI) 11% LOWER; reported Q2 EPS of $0.08, $0.02 better than the analyst estimate of $0.06. Revenue for the quarter came in at $31 million versus the consensus estimate of $31.31 million.\nZendesk (NYSE: ZEN) 7% LOWER; reported Q2 EPS of $0.13, $0.03 worse than the analyst estimate of $0.16. Revenue for the quarter came in at $318.2 million versus the consensus estimate of $319.79 million. Zendesk sees FY2021 revenue of $1.31-1.32 billion, versus the consensus of $1.31 billion. Zendesk sees Q3 2021 revenue of $332-337 billion, versus the consensus of $335.5 billion.\nSkyworks Solutions (NASDAQ: SWKS) 5.2% LOWER; reported Q3 EPS of $2.15, $0.01 better than the analyst estimate of $2.14. Revenue for the quarter came in at $1.12 billion versus the consensus estimate of $1.1 billion. Skyworks Solutions sees Q4 2021 EPS of $2.53-$2.48. Skyworks Solutions sees Q4 2021 revenue of $1.27-1.33 billion, versus the consensus of $1.22 billion.\nDexCom (NASDAQ: DXCM) 4.3% HIGHER; reported Q2 EPS of $0.76, $0.31 better than the analyst estimate of $0.45. Revenue for the quarter came in at $59.5 million versus the consensus estimate of $551.27 million. DexCom sees FY2021 revenue of $2.35-2.4 billion, versus the consensus of $2.34 billion.","news_type":1,"symbols_score_info":{"DXCM":0.9,"ERYP":0.9,"MSON":0.9,"SWKS":0.9,"TEAM":0.9,"ZEN":0.9,"ZYXI":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":808719478,"gmtCreate":1627610048094,"gmtModify":1633757804218,"author":{"id":"3566638874866921","authorId":"3566638874866921","name":"Syin23","avatar":"https://static.tigerbbs.com/5fe07bbe04f288a17e760d8b275d427f","vip":1,"crmLevel":3,"crmLevelSwitch":0,"idStr":"3566638874866921","authorIdStr":"3566638874866921"},"htmlText":"Omg... Roller coaster..&nbsp;[惊吓]&nbsp;","listText":"Omg... Roller coaster..&nbsp;[惊吓]&nbsp;","text":"Omg... Roller coaster.. [惊吓]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/808719478","repostId":2155182860,"repostType":4,"repost":{"id":"2155182860","kind":"news","pubTimestamp":1627603020,"share":"https://ttm.financial/m/news/2155182860?lang=&edition=full","pubTime":"2021-07-30 07:57","market":"us","language":"en","title":"After-Hours Stock Movers: ERYTECH Pharma shares jumped 140%","url":"https://stock-news.laohu8.com/highlight/detail?id=2155182860","media":"StreetInsider","summary":"After-Hours Stock Movers:\nERYTECH Pharma (Nasdaq: ERYP) 140% HIGHER; announced that the U.S. Food an","content":"<p>After-Hours Stock Movers:</p>\n<p>ERYTECH Pharma (Nasdaq: ERYP) 140% HIGHER; announced that the U.S. Food and Drug Administration (FDA) has granted eryaspase Fast Track designation for the treatment of acute lymphocytic leukemia (ALL) patients who have developed hypersensitivity reactions to E. coli-derived pegylated asparaginase (PEG-ASNase).</p>\n<p>Atlassian (NASDAQ: TEAM) 13.2% HIGHER; reported Q4 EPS of $0.24, $0.06 better than the analyst estimate of $0.18. Revenue for the quarter came in at $560 million versus the consensus estimate of $524.09 million. Atlassian sees Q1 2022 EPS of $0.38-$0.39, versus the consensus of $0.31. Atlassian sees Q1 2022 revenue of $575-590 million, versus the consensus of $540.89 million.</p>\n<p>Misonix, Inc. (Nasdaq: MSON) 12% HIGHER; <a href=\"https://laohu8.com/S/BIOV\">Bioventus Inc.</a> (Nasdaq: BVS) (Bioventus), a global leader in innovations for active healing, and Misonix, Inc. (Nasdaq: MSON) (Misonix), a provider of minimally invasive therapeutic ultrasonic technologies and regenerative medicine that enhance clinical outcomes, today announced that they have entered into a definitive agreement by which Bioventus will acquire Misonix in a cash-and-stock transaction.</p>\n<p><a href=\"https://laohu8.com/S/ZYXI\">Zynex, Inc.</a> (NASDAQ: ZYXI) 11% LOWER; reported Q2 EPS of $0.08, $0.02 better than the analyst estimate of $0.06. Revenue for the quarter came in at $31 million versus the consensus estimate of $31.31 million.</p>\n<p>Zendesk (NYSE: ZEN) 7% LOWER; reported Q2 EPS of $0.13, $0.03 worse than the analyst estimate of $0.16. Revenue for the quarter came in at $318.2 million versus the consensus estimate of $319.79 million. Zendesk sees FY2021 revenue of $1.31-1.32 billion, versus the consensus of $1.31 billion. Zendesk sees Q3 2021 revenue of $332-337 billion, versus the consensus of $335.5 billion.</p>\n<p>Skyworks Solutions (NASDAQ: SWKS) 5.2% LOWER; reported Q3 EPS of $2.15, $0.01 better than the analyst estimate of $2.14. Revenue for the quarter came in at $1.12 billion versus the consensus estimate of $1.1 billion. Skyworks Solutions sees Q4 2021 EPS of $2.53-$2.48. Skyworks Solutions sees Q4 2021 revenue of $1.27-1.33 billion, versus the consensus of $1.22 billion.</p>\n<p>DexCom (NASDAQ: DXCM) 4.3% HIGHER; reported Q2 EPS of $0.76, $0.31 better than the analyst estimate of $0.45. Revenue for the quarter came in at $59.5 million versus the consensus estimate of $551.27 million. DexCom sees FY2021 revenue of $2.35-2.4 billion, versus the consensus of $2.34 billion.</p>","source":"highlight_streetinsider","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>After-Hours Stock Movers: ERYTECH Pharma shares jumped 140%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAfter-Hours Stock Movers: ERYTECH Pharma shares jumped 140%\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-30 07:57 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.streetinsider.com/dr/news.php?id=18744154><strong>StreetInsider</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>After-Hours Stock Movers:\nERYTECH Pharma (Nasdaq: ERYP) 140% HIGHER; announced that the U.S. Food and Drug Administration (FDA) has granted eryaspase Fast Track designation for the treatment of acute ...</p>\n\n<a href=\"https://www.streetinsider.com/dr/news.php?id=18744154\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"DXCM":"德康医疗","TEAM":"Atlassian Corporation PLC","MSON":"Misonix Inc","SWKS":"思佳讯","ZYXI":"Zynex, Inc."},"source_url":"https://www.streetinsider.com/dr/news.php?id=18744154","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2155182860","content_text":"After-Hours Stock Movers:\nERYTECH Pharma (Nasdaq: ERYP) 140% HIGHER; announced that the U.S. Food and Drug Administration (FDA) has granted eryaspase Fast Track designation for the treatment of acute lymphocytic leukemia (ALL) patients who have developed hypersensitivity reactions to E. coli-derived pegylated asparaginase (PEG-ASNase).\nAtlassian (NASDAQ: TEAM) 13.2% HIGHER; reported Q4 EPS of $0.24, $0.06 better than the analyst estimate of $0.18. Revenue for the quarter came in at $560 million versus the consensus estimate of $524.09 million. Atlassian sees Q1 2022 EPS of $0.38-$0.39, versus the consensus of $0.31. Atlassian sees Q1 2022 revenue of $575-590 million, versus the consensus of $540.89 million.\nMisonix, Inc. (Nasdaq: MSON) 12% HIGHER; Bioventus Inc. (Nasdaq: BVS) (Bioventus), a global leader in innovations for active healing, and Misonix, Inc. (Nasdaq: MSON) (Misonix), a provider of minimally invasive therapeutic ultrasonic technologies and regenerative medicine that enhance clinical outcomes, today announced that they have entered into a definitive agreement by which Bioventus will acquire Misonix in a cash-and-stock transaction.\nZynex, Inc. (NASDAQ: ZYXI) 11% LOWER; reported Q2 EPS of $0.08, $0.02 better than the analyst estimate of $0.06. Revenue for the quarter came in at $31 million versus the consensus estimate of $31.31 million.\nZendesk (NYSE: ZEN) 7% LOWER; reported Q2 EPS of $0.13, $0.03 worse than the analyst estimate of $0.16. Revenue for the quarter came in at $318.2 million versus the consensus estimate of $319.79 million. Zendesk sees FY2021 revenue of $1.31-1.32 billion, versus the consensus of $1.31 billion. Zendesk sees Q3 2021 revenue of $332-337 billion, versus the consensus of $335.5 billion.\nSkyworks Solutions (NASDAQ: SWKS) 5.2% LOWER; reported Q3 EPS of $2.15, $0.01 better than the analyst estimate of $2.14. Revenue for the quarter came in at $1.12 billion versus the consensus estimate of $1.1 billion. Skyworks Solutions sees Q4 2021 EPS of $2.53-$2.48. Skyworks Solutions sees Q4 2021 revenue of $1.27-1.33 billion, versus the consensus of $1.22 billion.\nDexCom (NASDAQ: DXCM) 4.3% HIGHER; reported Q2 EPS of $0.76, $0.31 better than the analyst estimate of $0.45. Revenue for the quarter came in at $59.5 million versus the consensus estimate of $551.27 million. DexCom sees FY2021 revenue of $2.35-2.4 billion, versus the consensus of $2.34 billion.","news_type":1,"symbols_score_info":{"DXCM":0.9,"ERYP":0.9,"MSON":0.9,"SWKS":0.9,"TEAM":0.9,"ZEN":0.9,"ZYXI":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5375128,"gmtCreate":1627610078812,"gmtModify":1631894897636,"authorId":3580565594783380,"author":{"id":3580565594783380,"idStr":"3580565594783380","authorId":3580565594783380,"name":"Amins","avatar":"https://static.tigerbbs.com/e27267c412cea01bdd4a47d746ba7606","vip":1,"crmLevel":5,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":808719478,"type":1,"supId":0,"prevId":0,"content":"Hahah","text":"Hahah","html":"Hahah"}],"langContent":"CN"},{"id":808731687,"gmtCreate":1627609633649,"gmtModify":1633757811311,"author":{"id":"3586408007231136","authorId":"3586408007231136","name":"KeatWei","avatar":"https://static.tigerbbs.com/888c5c9e15d9720e77d1799e3ef80e42","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3586408007231136","authorIdStr":"3586408007231136"},"htmlText":"Like please&nbsp;","listText":"Like please&nbsp;","text":"Like please","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/808731687","repostId":2155182860,"repostType":4,"repost":{"id":"2155182860","kind":"news","pubTimestamp":1627603020,"share":"https://ttm.financial/m/news/2155182860?lang=&edition=full","pubTime":"2021-07-30 07:57","market":"us","language":"en","title":"After-Hours Stock Movers: ERYTECH Pharma shares jumped 140%","url":"https://stock-news.laohu8.com/highlight/detail?id=2155182860","media":"StreetInsider","summary":"After-Hours Stock Movers:\nERYTECH Pharma (Nasdaq: ERYP) 140% HIGHER; announced that the U.S. Food an","content":"<p>After-Hours Stock Movers:</p>\n<p>ERYTECH Pharma (Nasdaq: ERYP) 140% HIGHER; announced that the U.S. Food and Drug Administration (FDA) has granted eryaspase Fast Track designation for the treatment of acute lymphocytic leukemia (ALL) patients who have developed hypersensitivity reactions to E. coli-derived pegylated asparaginase (PEG-ASNase).</p>\n<p>Atlassian (NASDAQ: TEAM) 13.2% HIGHER; reported Q4 EPS of $0.24, $0.06 better than the analyst estimate of $0.18. Revenue for the quarter came in at $560 million versus the consensus estimate of $524.09 million. Atlassian sees Q1 2022 EPS of $0.38-$0.39, versus the consensus of $0.31. Atlassian sees Q1 2022 revenue of $575-590 million, versus the consensus of $540.89 million.</p>\n<p>Misonix, Inc. (Nasdaq: MSON) 12% HIGHER; <a href=\"https://laohu8.com/S/BIOV\">Bioventus Inc.</a> (Nasdaq: BVS) (Bioventus), a global leader in innovations for active healing, and Misonix, Inc. (Nasdaq: MSON) (Misonix), a provider of minimally invasive therapeutic ultrasonic technologies and regenerative medicine that enhance clinical outcomes, today announced that they have entered into a definitive agreement by which Bioventus will acquire Misonix in a cash-and-stock transaction.</p>\n<p><a href=\"https://laohu8.com/S/ZYXI\">Zynex, Inc.</a> (NASDAQ: ZYXI) 11% LOWER; reported Q2 EPS of $0.08, $0.02 better than the analyst estimate of $0.06. Revenue for the quarter came in at $31 million versus the consensus estimate of $31.31 million.</p>\n<p>Zendesk (NYSE: ZEN) 7% LOWER; reported Q2 EPS of $0.13, $0.03 worse than the analyst estimate of $0.16. Revenue for the quarter came in at $318.2 million versus the consensus estimate of $319.79 million. Zendesk sees FY2021 revenue of $1.31-1.32 billion, versus the consensus of $1.31 billion. Zendesk sees Q3 2021 revenue of $332-337 billion, versus the consensus of $335.5 billion.</p>\n<p>Skyworks Solutions (NASDAQ: SWKS) 5.2% LOWER; reported Q3 EPS of $2.15, $0.01 better than the analyst estimate of $2.14. Revenue for the quarter came in at $1.12 billion versus the consensus estimate of $1.1 billion. Skyworks Solutions sees Q4 2021 EPS of $2.53-$2.48. Skyworks Solutions sees Q4 2021 revenue of $1.27-1.33 billion, versus the consensus of $1.22 billion.</p>\n<p>DexCom (NASDAQ: DXCM) 4.3% HIGHER; reported Q2 EPS of $0.76, $0.31 better than the analyst estimate of $0.45. Revenue for the quarter came in at $59.5 million versus the consensus estimate of $551.27 million. DexCom sees FY2021 revenue of $2.35-2.4 billion, versus the consensus of $2.34 billion.</p>","source":"highlight_streetinsider","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>After-Hours Stock Movers: ERYTECH Pharma shares jumped 140%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAfter-Hours Stock Movers: ERYTECH Pharma shares jumped 140%\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-30 07:57 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.streetinsider.com/dr/news.php?id=18744154><strong>StreetInsider</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>After-Hours Stock Movers:\nERYTECH Pharma (Nasdaq: ERYP) 140% HIGHER; announced that the U.S. Food and Drug Administration (FDA) has granted eryaspase Fast Track designation for the treatment of acute ...</p>\n\n<a href=\"https://www.streetinsider.com/dr/news.php?id=18744154\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"DXCM":"德康医疗","TEAM":"Atlassian Corporation PLC","MSON":"Misonix Inc","SWKS":"思佳讯","ZYXI":"Zynex, Inc."},"source_url":"https://www.streetinsider.com/dr/news.php?id=18744154","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2155182860","content_text":"After-Hours Stock Movers:\nERYTECH Pharma (Nasdaq: ERYP) 140% HIGHER; announced that the U.S. Food and Drug Administration (FDA) has granted eryaspase Fast Track designation for the treatment of acute lymphocytic leukemia (ALL) patients who have developed hypersensitivity reactions to E. coli-derived pegylated asparaginase (PEG-ASNase).\nAtlassian (NASDAQ: TEAM) 13.2% HIGHER; reported Q4 EPS of $0.24, $0.06 better than the analyst estimate of $0.18. Revenue for the quarter came in at $560 million versus the consensus estimate of $524.09 million. Atlassian sees Q1 2022 EPS of $0.38-$0.39, versus the consensus of $0.31. Atlassian sees Q1 2022 revenue of $575-590 million, versus the consensus of $540.89 million.\nMisonix, Inc. (Nasdaq: MSON) 12% HIGHER; Bioventus Inc. (Nasdaq: BVS) (Bioventus), a global leader in innovations for active healing, and Misonix, Inc. (Nasdaq: MSON) (Misonix), a provider of minimally invasive therapeutic ultrasonic technologies and regenerative medicine that enhance clinical outcomes, today announced that they have entered into a definitive agreement by which Bioventus will acquire Misonix in a cash-and-stock transaction.\nZynex, Inc. (NASDAQ: ZYXI) 11% LOWER; reported Q2 EPS of $0.08, $0.02 better than the analyst estimate of $0.06. Revenue for the quarter came in at $31 million versus the consensus estimate of $31.31 million.\nZendesk (NYSE: ZEN) 7% LOWER; reported Q2 EPS of $0.13, $0.03 worse than the analyst estimate of $0.16. Revenue for the quarter came in at $318.2 million versus the consensus estimate of $319.79 million. Zendesk sees FY2021 revenue of $1.31-1.32 billion, versus the consensus of $1.31 billion. Zendesk sees Q3 2021 revenue of $332-337 billion, versus the consensus of $335.5 billion.\nSkyworks Solutions (NASDAQ: SWKS) 5.2% LOWER; reported Q3 EPS of $2.15, $0.01 better than the analyst estimate of $2.14. Revenue for the quarter came in at $1.12 billion versus the consensus estimate of $1.1 billion. Skyworks Solutions sees Q4 2021 EPS of $2.53-$2.48. Skyworks Solutions sees Q4 2021 revenue of $1.27-1.33 billion, versus the consensus of $1.22 billion.\nDexCom (NASDAQ: DXCM) 4.3% HIGHER; reported Q2 EPS of $0.76, $0.31 better than the analyst estimate of $0.45. Revenue for the quarter came in at $59.5 million versus the consensus estimate of $551.27 million. DexCom sees FY2021 revenue of $2.35-2.4 billion, versus the consensus of $2.34 billion.","news_type":1,"symbols_score_info":{"DXCM":0.9,"ERYP":0.9,"MSON":0.9,"SWKS":0.9,"TEAM":0.9,"ZEN":0.9,"ZYXI":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5375619,"gmtCreate":1627613580625,"gmtModify":1635164410094,"authorId":3582098623642517,"author":{"id":3582098623642517,"idStr":"3582098623642517","authorId":3582098623642517,"name":"小虎一飞冲天","avatar":"https://static.tigerbbs.com/1a55a61195830e019abf5d3cc69681b9","vip":1,"crmLevel":6,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":808731687,"type":1,"supId":0,"prevId":0,"content":"👍🏼","text":"👍🏼","html":"👍🏼"}],"langContent":"EN"},{"id":808702935,"gmtCreate":1627608807227,"gmtModify":1633757826359,"author":{"id":"3574754838536636","authorId":"3574754838536636","name":"Ameliakoh","avatar":"https://static.tigerbbs.com/4a747ab791603fb0a649736b10ec7454","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3574754838536636","authorIdStr":"3574754838536636"},"htmlText":"Pls like n comment 🙏","listText":"Pls like n comment 🙏","text":"Pls like n comment 🙏","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":9,"commentSize":5,"repostSize":0,"link":"https://laohu8.com/post/808702935","repostId":2155182860,"repostType":4,"repost":{"id":"2155182860","kind":"news","pubTimestamp":1627603020,"share":"https://ttm.financial/m/news/2155182860?lang=&edition=full","pubTime":"2021-07-30 07:57","market":"us","language":"en","title":"After-Hours Stock Movers: ERYTECH Pharma shares jumped 140%","url":"https://stock-news.laohu8.com/highlight/detail?id=2155182860","media":"StreetInsider","summary":"After-Hours Stock Movers:\nERYTECH Pharma (Nasdaq: ERYP) 140% HIGHER; announced that the U.S. Food an","content":"<p>After-Hours Stock Movers:</p>\n<p>ERYTECH Pharma (Nasdaq: ERYP) 140% HIGHER; announced that the U.S. Food and Drug Administration (FDA) has granted eryaspase Fast Track designation for the treatment of acute lymphocytic leukemia (ALL) patients who have developed hypersensitivity reactions to E. coli-derived pegylated asparaginase (PEG-ASNase).</p>\n<p>Atlassian (NASDAQ: TEAM) 13.2% HIGHER; reported Q4 EPS of $0.24, $0.06 better than the analyst estimate of $0.18. Revenue for the quarter came in at $560 million versus the consensus estimate of $524.09 million. Atlassian sees Q1 2022 EPS of $0.38-$0.39, versus the consensus of $0.31. Atlassian sees Q1 2022 revenue of $575-590 million, versus the consensus of $540.89 million.</p>\n<p>Misonix, Inc. (Nasdaq: MSON) 12% HIGHER; <a href=\"https://laohu8.com/S/BIOV\">Bioventus Inc.</a> (Nasdaq: BVS) (Bioventus), a global leader in innovations for active healing, and Misonix, Inc. (Nasdaq: MSON) (Misonix), a provider of minimally invasive therapeutic ultrasonic technologies and regenerative medicine that enhance clinical outcomes, today announced that they have entered into a definitive agreement by which Bioventus will acquire Misonix in a cash-and-stock transaction.</p>\n<p><a href=\"https://laohu8.com/S/ZYXI\">Zynex, Inc.</a> (NASDAQ: ZYXI) 11% LOWER; reported Q2 EPS of $0.08, $0.02 better than the analyst estimate of $0.06. Revenue for the quarter came in at $31 million versus the consensus estimate of $31.31 million.</p>\n<p>Zendesk (NYSE: ZEN) 7% LOWER; reported Q2 EPS of $0.13, $0.03 worse than the analyst estimate of $0.16. Revenue for the quarter came in at $318.2 million versus the consensus estimate of $319.79 million. Zendesk sees FY2021 revenue of $1.31-1.32 billion, versus the consensus of $1.31 billion. Zendesk sees Q3 2021 revenue of $332-337 billion, versus the consensus of $335.5 billion.</p>\n<p>Skyworks Solutions (NASDAQ: SWKS) 5.2% LOWER; reported Q3 EPS of $2.15, $0.01 better than the analyst estimate of $2.14. Revenue for the quarter came in at $1.12 billion versus the consensus estimate of $1.1 billion. Skyworks Solutions sees Q4 2021 EPS of $2.53-$2.48. Skyworks Solutions sees Q4 2021 revenue of $1.27-1.33 billion, versus the consensus of $1.22 billion.</p>\n<p>DexCom (NASDAQ: DXCM) 4.3% HIGHER; reported Q2 EPS of $0.76, $0.31 better than the analyst estimate of $0.45. Revenue for the quarter came in at $59.5 million versus the consensus estimate of $551.27 million. DexCom sees FY2021 revenue of $2.35-2.4 billion, versus the consensus of $2.34 billion.</p>","source":"highlight_streetinsider","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>After-Hours Stock Movers: ERYTECH Pharma shares jumped 140%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAfter-Hours Stock Movers: ERYTECH Pharma shares jumped 140%\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-30 07:57 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.streetinsider.com/dr/news.php?id=18744154><strong>StreetInsider</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>After-Hours Stock Movers:\nERYTECH Pharma (Nasdaq: ERYP) 140% HIGHER; announced that the U.S. Food and Drug Administration (FDA) has granted eryaspase Fast Track designation for the treatment of acute ...</p>\n\n<a href=\"https://www.streetinsider.com/dr/news.php?id=18744154\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"DXCM":"德康医疗","TEAM":"Atlassian Corporation PLC","MSON":"Misonix Inc","SWKS":"思佳讯","ZYXI":"Zynex, Inc."},"source_url":"https://www.streetinsider.com/dr/news.php?id=18744154","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2155182860","content_text":"After-Hours Stock Movers:\nERYTECH Pharma (Nasdaq: ERYP) 140% HIGHER; announced that the U.S. Food and Drug Administration (FDA) has granted eryaspase Fast Track designation for the treatment of acute lymphocytic leukemia (ALL) patients who have developed hypersensitivity reactions to E. coli-derived pegylated asparaginase (PEG-ASNase).\nAtlassian (NASDAQ: TEAM) 13.2% HIGHER; reported Q4 EPS of $0.24, $0.06 better than the analyst estimate of $0.18. Revenue for the quarter came in at $560 million versus the consensus estimate of $524.09 million. Atlassian sees Q1 2022 EPS of $0.38-$0.39, versus the consensus of $0.31. Atlassian sees Q1 2022 revenue of $575-590 million, versus the consensus of $540.89 million.\nMisonix, Inc. (Nasdaq: MSON) 12% HIGHER; Bioventus Inc. (Nasdaq: BVS) (Bioventus), a global leader in innovations for active healing, and Misonix, Inc. (Nasdaq: MSON) (Misonix), a provider of minimally invasive therapeutic ultrasonic technologies and regenerative medicine that enhance clinical outcomes, today announced that they have entered into a definitive agreement by which Bioventus will acquire Misonix in a cash-and-stock transaction.\nZynex, Inc. (NASDAQ: ZYXI) 11% LOWER; reported Q2 EPS of $0.08, $0.02 better than the analyst estimate of $0.06. Revenue for the quarter came in at $31 million versus the consensus estimate of $31.31 million.\nZendesk (NYSE: ZEN) 7% LOWER; reported Q2 EPS of $0.13, $0.03 worse than the analyst estimate of $0.16. Revenue for the quarter came in at $318.2 million versus the consensus estimate of $319.79 million. Zendesk sees FY2021 revenue of $1.31-1.32 billion, versus the consensus of $1.31 billion. Zendesk sees Q3 2021 revenue of $332-337 billion, versus the consensus of $335.5 billion.\nSkyworks Solutions (NASDAQ: SWKS) 5.2% LOWER; reported Q3 EPS of $2.15, $0.01 better than the analyst estimate of $2.14. Revenue for the quarter came in at $1.12 billion versus the consensus estimate of $1.1 billion. Skyworks Solutions sees Q4 2021 EPS of $2.53-$2.48. Skyworks Solutions sees Q4 2021 revenue of $1.27-1.33 billion, versus the consensus of $1.22 billion.\nDexCom (NASDAQ: DXCM) 4.3% HIGHER; reported Q2 EPS of $0.76, $0.31 better than the analyst estimate of $0.45. Revenue for the quarter came in at $59.5 million versus the consensus estimate of $551.27 million. DexCom sees FY2021 revenue of $2.35-2.4 billion, versus the consensus of $2.34 billion.","news_type":1,"symbols_score_info":{"DXCM":0.9,"ERYP":0.9,"MSON":0.9,"SWKS":0.9,"TEAM":0.9,"ZEN":0.9,"ZYXI":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5375066,"gmtCreate":1627609612122,"gmtModify":1635164462423,"authorId":3586408007231136,"author":{"id":3586408007231136,"idStr":"3586408007231136","authorId":3586408007231136,"name":"KeatWei","avatar":"https://static.tigerbbs.com/888c5c9e15d9720e77d1799e3ef80e42","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":808702935,"type":1,"supId":0,"prevId":0,"content":"Okay","text":"Okay","html":"Okay"},{"id":5375712,"gmtCreate":1627614474646,"gmtModify":1635164401608,"authorId":3574924778363716,"author":{"id":3574924778363716,"idStr":"3574924778363716","authorId":3574924778363716,"name":"sSS","avatar":"https://static.tigerbbs.com/6feafa4a828260badf8636e7a0776299","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":808702935,"type":1,"supId":0,"prevId":0,"content":".","text":".","html":"."},{"id":5383615,"gmtCreate":1627688546319,"gmtModify":1635163815905,"authorId":3579657215684313,"author":{"id":3579657215684313,"idStr":"3579657215684313","authorId":3579657215684313,"name":"Benly8","avatar":"https://static.tigerbbs.com/80f36222b1c1982caf217686d5a8431f","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":808702935,"type":1,"supId":0,"prevId":0,"content":"DonE, Pls like back thanks","text":"DonE, Pls like back thanks","html":"DonE, Pls like back thanks"},{"id":5388232,"gmtCreate":1627729171223,"gmtModify":1635163375289,"authorId":3584773168332448,"author":{"id":3584773168332448,"idStr":"3584773168332448","authorId":3584773168332448,"name":"ThomasNg007","avatar":"https://static.tigerbbs.com/89ba5408bae6b6c08a33ca86271ef073","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":808702935,"type":1,"supId":0,"prevId":0,"content":"Going up soon? ","text":"Going up soon? ","html":"Going up soon? "},{"id":5401038,"gmtCreate":1627887184597,"gmtModify":1635162137893,"authorId":3585617155516823,"author":{"id":3585617155516823,"idStr":"3585617155516823","authorId":3585617155516823,"name":"Baby Step 4","avatar":"https://static.tigerbbs.com/8ee1c9c06b2929c88e9f5bb3a24cf2d2","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":808702935,"type":1,"supId":0,"prevId":0,"content":"Ok ","text":"Ok ","html":"Ok "}],"langContent":"EN"},{"id":808708211,"gmtCreate":1627608707533,"gmtModify":1633757827569,"author":{"id":"3585567341976837","authorId":"3585567341976837","name":"Heidit","avatar":"https://static.tigerbbs.com/b15a14bcb1e7c71684448d84f3e500e7","vip":1,"crmLevel":4,"crmLevelSwitch":0,"idStr":"3585567341976837","authorIdStr":"3585567341976837"},"htmlText":"Cool read&nbsp;","listText":"Cool read&nbsp;","text":"Cool read","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/808708211","repostId":2155182860,"repostType":4,"repost":{"id":"2155182860","kind":"news","pubTimestamp":1627603020,"share":"https://ttm.financial/m/news/2155182860?lang=&edition=full","pubTime":"2021-07-30 07:57","market":"us","language":"en","title":"After-Hours Stock Movers: ERYTECH Pharma shares jumped 140%","url":"https://stock-news.laohu8.com/highlight/detail?id=2155182860","media":"StreetInsider","summary":"After-Hours Stock Movers:\nERYTECH Pharma (Nasdaq: ERYP) 140% HIGHER; announced that the U.S. Food an","content":"<p>After-Hours Stock Movers:</p>\n<p>ERYTECH Pharma (Nasdaq: ERYP) 140% HIGHER; announced that the U.S. Food and Drug Administration (FDA) has granted eryaspase Fast Track designation for the treatment of acute lymphocytic leukemia (ALL) patients who have developed hypersensitivity reactions to E. coli-derived pegylated asparaginase (PEG-ASNase).</p>\n<p>Atlassian (NASDAQ: TEAM) 13.2% HIGHER; reported Q4 EPS of $0.24, $0.06 better than the analyst estimate of $0.18. Revenue for the quarter came in at $560 million versus the consensus estimate of $524.09 million. Atlassian sees Q1 2022 EPS of $0.38-$0.39, versus the consensus of $0.31. Atlassian sees Q1 2022 revenue of $575-590 million, versus the consensus of $540.89 million.</p>\n<p>Misonix, Inc. (Nasdaq: MSON) 12% HIGHER; <a href=\"https://laohu8.com/S/BIOV\">Bioventus Inc.</a> (Nasdaq: BVS) (Bioventus), a global leader in innovations for active healing, and Misonix, Inc. (Nasdaq: MSON) (Misonix), a provider of minimally invasive therapeutic ultrasonic technologies and regenerative medicine that enhance clinical outcomes, today announced that they have entered into a definitive agreement by which Bioventus will acquire Misonix in a cash-and-stock transaction.</p>\n<p><a href=\"https://laohu8.com/S/ZYXI\">Zynex, Inc.</a> (NASDAQ: ZYXI) 11% LOWER; reported Q2 EPS of $0.08, $0.02 better than the analyst estimate of $0.06. Revenue for the quarter came in at $31 million versus the consensus estimate of $31.31 million.</p>\n<p>Zendesk (NYSE: ZEN) 7% LOWER; reported Q2 EPS of $0.13, $0.03 worse than the analyst estimate of $0.16. Revenue for the quarter came in at $318.2 million versus the consensus estimate of $319.79 million. Zendesk sees FY2021 revenue of $1.31-1.32 billion, versus the consensus of $1.31 billion. Zendesk sees Q3 2021 revenue of $332-337 billion, versus the consensus of $335.5 billion.</p>\n<p>Skyworks Solutions (NASDAQ: SWKS) 5.2% LOWER; reported Q3 EPS of $2.15, $0.01 better than the analyst estimate of $2.14. Revenue for the quarter came in at $1.12 billion versus the consensus estimate of $1.1 billion. Skyworks Solutions sees Q4 2021 EPS of $2.53-$2.48. Skyworks Solutions sees Q4 2021 revenue of $1.27-1.33 billion, versus the consensus of $1.22 billion.</p>\n<p>DexCom (NASDAQ: DXCM) 4.3% HIGHER; reported Q2 EPS of $0.76, $0.31 better than the analyst estimate of $0.45. Revenue for the quarter came in at $59.5 million versus the consensus estimate of $551.27 million. DexCom sees FY2021 revenue of $2.35-2.4 billion, versus the consensus of $2.34 billion.</p>","source":"highlight_streetinsider","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>After-Hours Stock Movers: ERYTECH Pharma shares jumped 140%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAfter-Hours Stock Movers: ERYTECH Pharma shares jumped 140%\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-30 07:57 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.streetinsider.com/dr/news.php?id=18744154><strong>StreetInsider</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>After-Hours Stock Movers:\nERYTECH Pharma (Nasdaq: ERYP) 140% HIGHER; announced that the U.S. Food and Drug Administration (FDA) has granted eryaspase Fast Track designation for the treatment of acute ...</p>\n\n<a href=\"https://www.streetinsider.com/dr/news.php?id=18744154\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"DXCM":"德康医疗","TEAM":"Atlassian Corporation PLC","MSON":"Misonix Inc","SWKS":"思佳讯","ZYXI":"Zynex, Inc."},"source_url":"https://www.streetinsider.com/dr/news.php?id=18744154","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2155182860","content_text":"After-Hours Stock Movers:\nERYTECH Pharma (Nasdaq: ERYP) 140% HIGHER; announced that the U.S. Food and Drug Administration (FDA) has granted eryaspase Fast Track designation for the treatment of acute lymphocytic leukemia (ALL) patients who have developed hypersensitivity reactions to E. coli-derived pegylated asparaginase (PEG-ASNase).\nAtlassian (NASDAQ: TEAM) 13.2% HIGHER; reported Q4 EPS of $0.24, $0.06 better than the analyst estimate of $0.18. Revenue for the quarter came in at $560 million versus the consensus estimate of $524.09 million. Atlassian sees Q1 2022 EPS of $0.38-$0.39, versus the consensus of $0.31. Atlassian sees Q1 2022 revenue of $575-590 million, versus the consensus of $540.89 million.\nMisonix, Inc. (Nasdaq: MSON) 12% HIGHER; Bioventus Inc. (Nasdaq: BVS) (Bioventus), a global leader in innovations for active healing, and Misonix, Inc. (Nasdaq: MSON) (Misonix), a provider of minimally invasive therapeutic ultrasonic technologies and regenerative medicine that enhance clinical outcomes, today announced that they have entered into a definitive agreement by which Bioventus will acquire Misonix in a cash-and-stock transaction.\nZynex, Inc. (NASDAQ: ZYXI) 11% LOWER; reported Q2 EPS of $0.08, $0.02 better than the analyst estimate of $0.06. Revenue for the quarter came in at $31 million versus the consensus estimate of $31.31 million.\nZendesk (NYSE: ZEN) 7% LOWER; reported Q2 EPS of $0.13, $0.03 worse than the analyst estimate of $0.16. Revenue for the quarter came in at $318.2 million versus the consensus estimate of $319.79 million. Zendesk sees FY2021 revenue of $1.31-1.32 billion, versus the consensus of $1.31 billion. Zendesk sees Q3 2021 revenue of $332-337 billion, versus the consensus of $335.5 billion.\nSkyworks Solutions (NASDAQ: SWKS) 5.2% LOWER; reported Q3 EPS of $2.15, $0.01 better than the analyst estimate of $2.14. Revenue for the quarter came in at $1.12 billion versus the consensus estimate of $1.1 billion. Skyworks Solutions sees Q4 2021 EPS of $2.53-$2.48. Skyworks Solutions sees Q4 2021 revenue of $1.27-1.33 billion, versus the consensus of $1.22 billion.\nDexCom (NASDAQ: DXCM) 4.3% HIGHER; reported Q2 EPS of $0.76, $0.31 better than the analyst estimate of $0.45. Revenue for the quarter came in at $59.5 million versus the consensus estimate of $551.27 million. DexCom sees FY2021 revenue of $2.35-2.4 billion, versus the consensus of $2.34 billion.","news_type":1,"symbols_score_info":{"DXCM":0.9,"ERYP":0.9,"MSON":0.9,"SWKS":0.9,"TEAM":0.9,"ZEN":0.9,"ZYXI":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":808470007,"gmtCreate":1627608127009,"gmtModify":1633757838779,"author":{"id":"3581918772657410","authorId":"3581918772657410","name":"Hesliut","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":4,"crmLevelSwitch":0,"idStr":"3581918772657410","authorIdStr":"3581918772657410"},"htmlText":"Like please~","listText":"Like please~","text":"Like please~","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/808470007","repostId":2155182860,"repostType":4,"repost":{"id":"2155182860","kind":"news","pubTimestamp":1627603020,"share":"https://ttm.financial/m/news/2155182860?lang=&edition=full","pubTime":"2021-07-30 07:57","market":"us","language":"en","title":"After-Hours Stock Movers: ERYTECH Pharma shares jumped 140%","url":"https://stock-news.laohu8.com/highlight/detail?id=2155182860","media":"StreetInsider","summary":"After-Hours Stock Movers:\nERYTECH Pharma (Nasdaq: ERYP) 140% HIGHER; announced that the U.S. Food an","content":"<p>After-Hours Stock Movers:</p>\n<p>ERYTECH Pharma (Nasdaq: ERYP) 140% HIGHER; announced that the U.S. Food and Drug Administration (FDA) has granted eryaspase Fast Track designation for the treatment of acute lymphocytic leukemia (ALL) patients who have developed hypersensitivity reactions to E. coli-derived pegylated asparaginase (PEG-ASNase).</p>\n<p>Atlassian (NASDAQ: TEAM) 13.2% HIGHER; reported Q4 EPS of $0.24, $0.06 better than the analyst estimate of $0.18. Revenue for the quarter came in at $560 million versus the consensus estimate of $524.09 million. Atlassian sees Q1 2022 EPS of $0.38-$0.39, versus the consensus of $0.31. Atlassian sees Q1 2022 revenue of $575-590 million, versus the consensus of $540.89 million.</p>\n<p>Misonix, Inc. (Nasdaq: MSON) 12% HIGHER; <a href=\"https://laohu8.com/S/BIOV\">Bioventus Inc.</a> (Nasdaq: BVS) (Bioventus), a global leader in innovations for active healing, and Misonix, Inc. (Nasdaq: MSON) (Misonix), a provider of minimally invasive therapeutic ultrasonic technologies and regenerative medicine that enhance clinical outcomes, today announced that they have entered into a definitive agreement by which Bioventus will acquire Misonix in a cash-and-stock transaction.</p>\n<p><a href=\"https://laohu8.com/S/ZYXI\">Zynex, Inc.</a> (NASDAQ: ZYXI) 11% LOWER; reported Q2 EPS of $0.08, $0.02 better than the analyst estimate of $0.06. Revenue for the quarter came in at $31 million versus the consensus estimate of $31.31 million.</p>\n<p>Zendesk (NYSE: ZEN) 7% LOWER; reported Q2 EPS of $0.13, $0.03 worse than the analyst estimate of $0.16. Revenue for the quarter came in at $318.2 million versus the consensus estimate of $319.79 million. Zendesk sees FY2021 revenue of $1.31-1.32 billion, versus the consensus of $1.31 billion. Zendesk sees Q3 2021 revenue of $332-337 billion, versus the consensus of $335.5 billion.</p>\n<p>Skyworks Solutions (NASDAQ: SWKS) 5.2% LOWER; reported Q3 EPS of $2.15, $0.01 better than the analyst estimate of $2.14. Revenue for the quarter came in at $1.12 billion versus the consensus estimate of $1.1 billion. Skyworks Solutions sees Q4 2021 EPS of $2.53-$2.48. Skyworks Solutions sees Q4 2021 revenue of $1.27-1.33 billion, versus the consensus of $1.22 billion.</p>\n<p>DexCom (NASDAQ: DXCM) 4.3% HIGHER; reported Q2 EPS of $0.76, $0.31 better than the analyst estimate of $0.45. Revenue for the quarter came in at $59.5 million versus the consensus estimate of $551.27 million. DexCom sees FY2021 revenue of $2.35-2.4 billion, versus the consensus of $2.34 billion.</p>","source":"highlight_streetinsider","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>After-Hours Stock Movers: ERYTECH Pharma shares jumped 140%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAfter-Hours Stock Movers: ERYTECH Pharma shares jumped 140%\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-30 07:57 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.streetinsider.com/dr/news.php?id=18744154><strong>StreetInsider</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>After-Hours Stock Movers:\nERYTECH Pharma (Nasdaq: ERYP) 140% HIGHER; announced that the U.S. Food and Drug Administration (FDA) has granted eryaspase Fast Track designation for the treatment of acute ...</p>\n\n<a href=\"https://www.streetinsider.com/dr/news.php?id=18744154\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"DXCM":"德康医疗","TEAM":"Atlassian Corporation PLC","MSON":"Misonix Inc","SWKS":"思佳讯","ZYXI":"Zynex, Inc."},"source_url":"https://www.streetinsider.com/dr/news.php?id=18744154","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2155182860","content_text":"After-Hours Stock Movers:\nERYTECH Pharma (Nasdaq: ERYP) 140% HIGHER; announced that the U.S. Food and Drug Administration (FDA) has granted eryaspase Fast Track designation for the treatment of acute lymphocytic leukemia (ALL) patients who have developed hypersensitivity reactions to E. coli-derived pegylated asparaginase (PEG-ASNase).\nAtlassian (NASDAQ: TEAM) 13.2% HIGHER; reported Q4 EPS of $0.24, $0.06 better than the analyst estimate of $0.18. Revenue for the quarter came in at $560 million versus the consensus estimate of $524.09 million. Atlassian sees Q1 2022 EPS of $0.38-$0.39, versus the consensus of $0.31. Atlassian sees Q1 2022 revenue of $575-590 million, versus the consensus of $540.89 million.\nMisonix, Inc. (Nasdaq: MSON) 12% HIGHER; Bioventus Inc. (Nasdaq: BVS) (Bioventus), a global leader in innovations for active healing, and Misonix, Inc. (Nasdaq: MSON) (Misonix), a provider of minimally invasive therapeutic ultrasonic technologies and regenerative medicine that enhance clinical outcomes, today announced that they have entered into a definitive agreement by which Bioventus will acquire Misonix in a cash-and-stock transaction.\nZynex, Inc. (NASDAQ: ZYXI) 11% LOWER; reported Q2 EPS of $0.08, $0.02 better than the analyst estimate of $0.06. Revenue for the quarter came in at $31 million versus the consensus estimate of $31.31 million.\nZendesk (NYSE: ZEN) 7% LOWER; reported Q2 EPS of $0.13, $0.03 worse than the analyst estimate of $0.16. Revenue for the quarter came in at $318.2 million versus the consensus estimate of $319.79 million. Zendesk sees FY2021 revenue of $1.31-1.32 billion, versus the consensus of $1.31 billion. Zendesk sees Q3 2021 revenue of $332-337 billion, versus the consensus of $335.5 billion.\nSkyworks Solutions (NASDAQ: SWKS) 5.2% LOWER; reported Q3 EPS of $2.15, $0.01 better than the analyst estimate of $2.14. Revenue for the quarter came in at $1.12 billion versus the consensus estimate of $1.1 billion. Skyworks Solutions sees Q4 2021 EPS of $2.53-$2.48. Skyworks Solutions sees Q4 2021 revenue of $1.27-1.33 billion, versus the consensus of $1.22 billion.\nDexCom (NASDAQ: DXCM) 4.3% HIGHER; reported Q2 EPS of $0.76, $0.31 better than the analyst estimate of $0.45. Revenue for the quarter came in at $59.5 million versus the consensus estimate of $551.27 million. DexCom sees FY2021 revenue of $2.35-2.4 billion, versus the consensus of $2.34 billion.","news_type":1,"symbols_score_info":{"DXCM":0.9,"ERYP":0.9,"MSON":0.9,"SWKS":0.9,"TEAM":0.9,"ZEN":0.9,"ZYXI":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":808422038,"gmtCreate":1627607095124,"gmtModify":1631894024419,"author":{"id":"3581145874192062","authorId":"3581145874192062","name":"Blurking","avatar":"https://static.tigerbbs.com/ed860cb4f3525c0719e435441ea282e9","vip":1,"crmLevel":6,"crmLevelSwitch":0,"idStr":"3581145874192062","authorIdStr":"3581145874192062"},"htmlText":"Good news for investor and patients&nbsp;","listText":"Good news for investor and patients&nbsp;","text":"Good news for investor and patients","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/808422038","repostId":2155182860,"repostType":4,"repost":{"id":"2155182860","kind":"news","pubTimestamp":1627603020,"share":"https://ttm.financial/m/news/2155182860?lang=&edition=full","pubTime":"2021-07-30 07:57","market":"us","language":"en","title":"After-Hours Stock Movers: ERYTECH Pharma shares jumped 140%","url":"https://stock-news.laohu8.com/highlight/detail?id=2155182860","media":"StreetInsider","summary":"After-Hours Stock Movers:\nERYTECH Pharma (Nasdaq: ERYP) 140% HIGHER; announced that the U.S. Food an","content":"<p>After-Hours Stock Movers:</p>\n<p>ERYTECH Pharma (Nasdaq: ERYP) 140% HIGHER; announced that the U.S. Food and Drug Administration (FDA) has granted eryaspase Fast Track designation for the treatment of acute lymphocytic leukemia (ALL) patients who have developed hypersensitivity reactions to E. coli-derived pegylated asparaginase (PEG-ASNase).</p>\n<p>Atlassian (NASDAQ: TEAM) 13.2% HIGHER; reported Q4 EPS of $0.24, $0.06 better than the analyst estimate of $0.18. Revenue for the quarter came in at $560 million versus the consensus estimate of $524.09 million. Atlassian sees Q1 2022 EPS of $0.38-$0.39, versus the consensus of $0.31. Atlassian sees Q1 2022 revenue of $575-590 million, versus the consensus of $540.89 million.</p>\n<p>Misonix, Inc. (Nasdaq: MSON) 12% HIGHER; <a href=\"https://laohu8.com/S/BIOV\">Bioventus Inc.</a> (Nasdaq: BVS) (Bioventus), a global leader in innovations for active healing, and Misonix, Inc. (Nasdaq: MSON) (Misonix), a provider of minimally invasive therapeutic ultrasonic technologies and regenerative medicine that enhance clinical outcomes, today announced that they have entered into a definitive agreement by which Bioventus will acquire Misonix in a cash-and-stock transaction.</p>\n<p><a href=\"https://laohu8.com/S/ZYXI\">Zynex, Inc.</a> (NASDAQ: ZYXI) 11% LOWER; reported Q2 EPS of $0.08, $0.02 better than the analyst estimate of $0.06. Revenue for the quarter came in at $31 million versus the consensus estimate of $31.31 million.</p>\n<p>Zendesk (NYSE: ZEN) 7% LOWER; reported Q2 EPS of $0.13, $0.03 worse than the analyst estimate of $0.16. Revenue for the quarter came in at $318.2 million versus the consensus estimate of $319.79 million. Zendesk sees FY2021 revenue of $1.31-1.32 billion, versus the consensus of $1.31 billion. Zendesk sees Q3 2021 revenue of $332-337 billion, versus the consensus of $335.5 billion.</p>\n<p>Skyworks Solutions (NASDAQ: SWKS) 5.2% LOWER; reported Q3 EPS of $2.15, $0.01 better than the analyst estimate of $2.14. Revenue for the quarter came in at $1.12 billion versus the consensus estimate of $1.1 billion. Skyworks Solutions sees Q4 2021 EPS of $2.53-$2.48. Skyworks Solutions sees Q4 2021 revenue of $1.27-1.33 billion, versus the consensus of $1.22 billion.</p>\n<p>DexCom (NASDAQ: DXCM) 4.3% HIGHER; reported Q2 EPS of $0.76, $0.31 better than the analyst estimate of $0.45. Revenue for the quarter came in at $59.5 million versus the consensus estimate of $551.27 million. DexCom sees FY2021 revenue of $2.35-2.4 billion, versus the consensus of $2.34 billion.</p>","source":"highlight_streetinsider","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>After-Hours Stock Movers: ERYTECH Pharma shares jumped 140%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAfter-Hours Stock Movers: ERYTECH Pharma shares jumped 140%\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-30 07:57 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.streetinsider.com/dr/news.php?id=18744154><strong>StreetInsider</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>After-Hours Stock Movers:\nERYTECH Pharma (Nasdaq: ERYP) 140% HIGHER; announced that the U.S. Food and Drug Administration (FDA) has granted eryaspase Fast Track designation for the treatment of acute ...</p>\n\n<a href=\"https://www.streetinsider.com/dr/news.php?id=18744154\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"DXCM":"德康医疗","TEAM":"Atlassian Corporation PLC","MSON":"Misonix Inc","SWKS":"思佳讯","ZYXI":"Zynex, Inc."},"source_url":"https://www.streetinsider.com/dr/news.php?id=18744154","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2155182860","content_text":"After-Hours Stock Movers:\nERYTECH Pharma (Nasdaq: ERYP) 140% HIGHER; announced that the U.S. Food and Drug Administration (FDA) has granted eryaspase Fast Track designation for the treatment of acute lymphocytic leukemia (ALL) patients who have developed hypersensitivity reactions to E. coli-derived pegylated asparaginase (PEG-ASNase).\nAtlassian (NASDAQ: TEAM) 13.2% HIGHER; reported Q4 EPS of $0.24, $0.06 better than the analyst estimate of $0.18. Revenue for the quarter came in at $560 million versus the consensus estimate of $524.09 million. Atlassian sees Q1 2022 EPS of $0.38-$0.39, versus the consensus of $0.31. Atlassian sees Q1 2022 revenue of $575-590 million, versus the consensus of $540.89 million.\nMisonix, Inc. (Nasdaq: MSON) 12% HIGHER; Bioventus Inc. (Nasdaq: BVS) (Bioventus), a global leader in innovations for active healing, and Misonix, Inc. (Nasdaq: MSON) (Misonix), a provider of minimally invasive therapeutic ultrasonic technologies and regenerative medicine that enhance clinical outcomes, today announced that they have entered into a definitive agreement by which Bioventus will acquire Misonix in a cash-and-stock transaction.\nZynex, Inc. (NASDAQ: ZYXI) 11% LOWER; reported Q2 EPS of $0.08, $0.02 better than the analyst estimate of $0.06. Revenue for the quarter came in at $31 million versus the consensus estimate of $31.31 million.\nZendesk (NYSE: ZEN) 7% LOWER; reported Q2 EPS of $0.13, $0.03 worse than the analyst estimate of $0.16. Revenue for the quarter came in at $318.2 million versus the consensus estimate of $319.79 million. Zendesk sees FY2021 revenue of $1.31-1.32 billion, versus the consensus of $1.31 billion. Zendesk sees Q3 2021 revenue of $332-337 billion, versus the consensus of $335.5 billion.\nSkyworks Solutions (NASDAQ: SWKS) 5.2% LOWER; reported Q3 EPS of $2.15, $0.01 better than the analyst estimate of $2.14. Revenue for the quarter came in at $1.12 billion versus the consensus estimate of $1.1 billion. Skyworks Solutions sees Q4 2021 EPS of $2.53-$2.48. Skyworks Solutions sees Q4 2021 revenue of $1.27-1.33 billion, versus the consensus of $1.22 billion.\nDexCom (NASDAQ: DXCM) 4.3% HIGHER; reported Q2 EPS of $0.76, $0.31 better than the analyst estimate of $0.45. Revenue for the quarter came in at $59.5 million versus the consensus estimate of $551.27 million. DexCom sees FY2021 revenue of $2.35-2.4 billion, versus the consensus of $2.34 billion.","news_type":1,"symbols_score_info":{"DXCM":0.9,"ERYP":0.9,"MSON":0.9,"SWKS":0.9,"TEAM":0.9,"ZEN":0.9,"ZYXI":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5374800,"gmtCreate":1627608141133,"gmtModify":1631894032085,"authorId":3581918772657410,"author":{"id":3581918772657410,"idStr":"3581918772657410","authorId":3581918772657410,"name":"Hesliut","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":4,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":808422038,"type":1,"supId":0,"prevId":0,"content":"Agree!","text":"Agree!","html":"Agree!"}],"langContent":"EN"},{"id":808465957,"gmtCreate":1627606679779,"gmtModify":1633757866509,"author":{"id":"4087997917943030","authorId":"4087997917943030","name":"June陈","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"4087997917943030","authorIdStr":"4087997917943030"},"htmlText":"Power.","listText":"Power.","text":"Power.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/808465957","repostId":2155182860,"repostType":4,"repost":{"id":"2155182860","kind":"news","pubTimestamp":1627603020,"share":"https://ttm.financial/m/news/2155182860?lang=&edition=full","pubTime":"2021-07-30 07:57","market":"us","language":"en","title":"After-Hours Stock Movers: ERYTECH Pharma shares jumped 140%","url":"https://stock-news.laohu8.com/highlight/detail?id=2155182860","media":"StreetInsider","summary":"After-Hours Stock Movers:\nERYTECH Pharma (Nasdaq: ERYP) 140% HIGHER; announced that the U.S. Food an","content":"<p>After-Hours Stock Movers:</p>\n<p>ERYTECH Pharma (Nasdaq: ERYP) 140% HIGHER; announced that the U.S. Food and Drug Administration (FDA) has granted eryaspase Fast Track designation for the treatment of acute lymphocytic leukemia (ALL) patients who have developed hypersensitivity reactions to E. coli-derived pegylated asparaginase (PEG-ASNase).</p>\n<p>Atlassian (NASDAQ: TEAM) 13.2% HIGHER; reported Q4 EPS of $0.24, $0.06 better than the analyst estimate of $0.18. Revenue for the quarter came in at $560 million versus the consensus estimate of $524.09 million. Atlassian sees Q1 2022 EPS of $0.38-$0.39, versus the consensus of $0.31. Atlassian sees Q1 2022 revenue of $575-590 million, versus the consensus of $540.89 million.</p>\n<p>Misonix, Inc. (Nasdaq: MSON) 12% HIGHER; <a href=\"https://laohu8.com/S/BIOV\">Bioventus Inc.</a> (Nasdaq: BVS) (Bioventus), a global leader in innovations for active healing, and Misonix, Inc. (Nasdaq: MSON) (Misonix), a provider of minimally invasive therapeutic ultrasonic technologies and regenerative medicine that enhance clinical outcomes, today announced that they have entered into a definitive agreement by which Bioventus will acquire Misonix in a cash-and-stock transaction.</p>\n<p><a href=\"https://laohu8.com/S/ZYXI\">Zynex, Inc.</a> (NASDAQ: ZYXI) 11% LOWER; reported Q2 EPS of $0.08, $0.02 better than the analyst estimate of $0.06. Revenue for the quarter came in at $31 million versus the consensus estimate of $31.31 million.</p>\n<p>Zendesk (NYSE: ZEN) 7% LOWER; reported Q2 EPS of $0.13, $0.03 worse than the analyst estimate of $0.16. Revenue for the quarter came in at $318.2 million versus the consensus estimate of $319.79 million. Zendesk sees FY2021 revenue of $1.31-1.32 billion, versus the consensus of $1.31 billion. Zendesk sees Q3 2021 revenue of $332-337 billion, versus the consensus of $335.5 billion.</p>\n<p>Skyworks Solutions (NASDAQ: SWKS) 5.2% LOWER; reported Q3 EPS of $2.15, $0.01 better than the analyst estimate of $2.14. Revenue for the quarter came in at $1.12 billion versus the consensus estimate of $1.1 billion. Skyworks Solutions sees Q4 2021 EPS of $2.53-$2.48. Skyworks Solutions sees Q4 2021 revenue of $1.27-1.33 billion, versus the consensus of $1.22 billion.</p>\n<p>DexCom (NASDAQ: DXCM) 4.3% HIGHER; reported Q2 EPS of $0.76, $0.31 better than the analyst estimate of $0.45. Revenue for the quarter came in at $59.5 million versus the consensus estimate of $551.27 million. DexCom sees FY2021 revenue of $2.35-2.4 billion, versus the consensus of $2.34 billion.</p>","source":"highlight_streetinsider","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>After-Hours Stock Movers: ERYTECH Pharma shares jumped 140%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAfter-Hours Stock Movers: ERYTECH Pharma shares jumped 140%\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-30 07:57 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.streetinsider.com/dr/news.php?id=18744154><strong>StreetInsider</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>After-Hours Stock Movers:\nERYTECH Pharma (Nasdaq: ERYP) 140% HIGHER; announced that the U.S. Food and Drug Administration (FDA) has granted eryaspase Fast Track designation for the treatment of acute ...</p>\n\n<a href=\"https://www.streetinsider.com/dr/news.php?id=18744154\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"DXCM":"德康医疗","TEAM":"Atlassian Corporation PLC","MSON":"Misonix Inc","SWKS":"思佳讯","ZYXI":"Zynex, Inc."},"source_url":"https://www.streetinsider.com/dr/news.php?id=18744154","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2155182860","content_text":"After-Hours Stock Movers:\nERYTECH Pharma (Nasdaq: ERYP) 140% HIGHER; announced that the U.S. Food and Drug Administration (FDA) has granted eryaspase Fast Track designation for the treatment of acute lymphocytic leukemia (ALL) patients who have developed hypersensitivity reactions to E. coli-derived pegylated asparaginase (PEG-ASNase).\nAtlassian (NASDAQ: TEAM) 13.2% HIGHER; reported Q4 EPS of $0.24, $0.06 better than the analyst estimate of $0.18. Revenue for the quarter came in at $560 million versus the consensus estimate of $524.09 million. Atlassian sees Q1 2022 EPS of $0.38-$0.39, versus the consensus of $0.31. Atlassian sees Q1 2022 revenue of $575-590 million, versus the consensus of $540.89 million.\nMisonix, Inc. (Nasdaq: MSON) 12% HIGHER; Bioventus Inc. (Nasdaq: BVS) (Bioventus), a global leader in innovations for active healing, and Misonix, Inc. (Nasdaq: MSON) (Misonix), a provider of minimally invasive therapeutic ultrasonic technologies and regenerative medicine that enhance clinical outcomes, today announced that they have entered into a definitive agreement by which Bioventus will acquire Misonix in a cash-and-stock transaction.\nZynex, Inc. (NASDAQ: ZYXI) 11% LOWER; reported Q2 EPS of $0.08, $0.02 better than the analyst estimate of $0.06. Revenue for the quarter came in at $31 million versus the consensus estimate of $31.31 million.\nZendesk (NYSE: ZEN) 7% LOWER; reported Q2 EPS of $0.13, $0.03 worse than the analyst estimate of $0.16. Revenue for the quarter came in at $318.2 million versus the consensus estimate of $319.79 million. Zendesk sees FY2021 revenue of $1.31-1.32 billion, versus the consensus of $1.31 billion. Zendesk sees Q3 2021 revenue of $332-337 billion, versus the consensus of $335.5 billion.\nSkyworks Solutions (NASDAQ: SWKS) 5.2% LOWER; reported Q3 EPS of $2.15, $0.01 better than the analyst estimate of $2.14. Revenue for the quarter came in at $1.12 billion versus the consensus estimate of $1.1 billion. Skyworks Solutions sees Q4 2021 EPS of $2.53-$2.48. Skyworks Solutions sees Q4 2021 revenue of $1.27-1.33 billion, versus the consensus of $1.22 billion.\nDexCom (NASDAQ: DXCM) 4.3% HIGHER; reported Q2 EPS of $0.76, $0.31 better than the analyst estimate of $0.45. Revenue for the quarter came in at $59.5 million versus the consensus estimate of $551.27 million. DexCom sees FY2021 revenue of $2.35-2.4 billion, versus the consensus of $2.34 billion.","news_type":1,"symbols_score_info":{"DXCM":0.9,"ERYP":0.9,"MSON":0.9,"SWKS":0.9,"TEAM":0.9,"ZEN":0.9,"ZYXI":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":808468466,"gmtCreate":1627606590955,"gmtModify":1633757869003,"author":{"id":"3582151718585472","authorId":"3582151718585472","name":"FrederickL","avatar":"https://static.tigerbbs.com/21ae0da315b7fd514ea9d30bfa0d125a","vip":1,"crmLevel":6,"crmLevelSwitch":0,"idStr":"3582151718585472","authorIdStr":"3582151718585472"},"htmlText":"Great!","listText":"Great!","text":"Great!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/808468466","repostId":2155182860,"repostType":4,"repost":{"id":"2155182860","kind":"news","pubTimestamp":1627603020,"share":"https://ttm.financial/m/news/2155182860?lang=&edition=full","pubTime":"2021-07-30 07:57","market":"us","language":"en","title":"After-Hours Stock Movers: ERYTECH Pharma shares jumped 140%","url":"https://stock-news.laohu8.com/highlight/detail?id=2155182860","media":"StreetInsider","summary":"After-Hours Stock Movers:\nERYTECH Pharma (Nasdaq: ERYP) 140% HIGHER; announced that the U.S. Food an","content":"<p>After-Hours Stock Movers:</p>\n<p>ERYTECH Pharma (Nasdaq: ERYP) 140% HIGHER; announced that the U.S. Food and Drug Administration (FDA) has granted eryaspase Fast Track designation for the treatment of acute lymphocytic leukemia (ALL) patients who have developed hypersensitivity reactions to E. coli-derived pegylated asparaginase (PEG-ASNase).</p>\n<p>Atlassian (NASDAQ: TEAM) 13.2% HIGHER; reported Q4 EPS of $0.24, $0.06 better than the analyst estimate of $0.18. Revenue for the quarter came in at $560 million versus the consensus estimate of $524.09 million. Atlassian sees Q1 2022 EPS of $0.38-$0.39, versus the consensus of $0.31. Atlassian sees Q1 2022 revenue of $575-590 million, versus the consensus of $540.89 million.</p>\n<p>Misonix, Inc. (Nasdaq: MSON) 12% HIGHER; <a href=\"https://laohu8.com/S/BIOV\">Bioventus Inc.</a> (Nasdaq: BVS) (Bioventus), a global leader in innovations for active healing, and Misonix, Inc. (Nasdaq: MSON) (Misonix), a provider of minimally invasive therapeutic ultrasonic technologies and regenerative medicine that enhance clinical outcomes, today announced that they have entered into a definitive agreement by which Bioventus will acquire Misonix in a cash-and-stock transaction.</p>\n<p><a href=\"https://laohu8.com/S/ZYXI\">Zynex, Inc.</a> (NASDAQ: ZYXI) 11% LOWER; reported Q2 EPS of $0.08, $0.02 better than the analyst estimate of $0.06. Revenue for the quarter came in at $31 million versus the consensus estimate of $31.31 million.</p>\n<p>Zendesk (NYSE: ZEN) 7% LOWER; reported Q2 EPS of $0.13, $0.03 worse than the analyst estimate of $0.16. Revenue for the quarter came in at $318.2 million versus the consensus estimate of $319.79 million. Zendesk sees FY2021 revenue of $1.31-1.32 billion, versus the consensus of $1.31 billion. Zendesk sees Q3 2021 revenue of $332-337 billion, versus the consensus of $335.5 billion.</p>\n<p>Skyworks Solutions (NASDAQ: SWKS) 5.2% LOWER; reported Q3 EPS of $2.15, $0.01 better than the analyst estimate of $2.14. Revenue for the quarter came in at $1.12 billion versus the consensus estimate of $1.1 billion. Skyworks Solutions sees Q4 2021 EPS of $2.53-$2.48. Skyworks Solutions sees Q4 2021 revenue of $1.27-1.33 billion, versus the consensus of $1.22 billion.</p>\n<p>DexCom (NASDAQ: DXCM) 4.3% HIGHER; reported Q2 EPS of $0.76, $0.31 better than the analyst estimate of $0.45. Revenue for the quarter came in at $59.5 million versus the consensus estimate of $551.27 million. DexCom sees FY2021 revenue of $2.35-2.4 billion, versus the consensus of $2.34 billion.</p>","source":"highlight_streetinsider","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>After-Hours Stock Movers: ERYTECH Pharma shares jumped 140%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAfter-Hours Stock Movers: ERYTECH Pharma shares jumped 140%\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-30 07:57 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.streetinsider.com/dr/news.php?id=18744154><strong>StreetInsider</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>After-Hours Stock Movers:\nERYTECH Pharma (Nasdaq: ERYP) 140% HIGHER; announced that the U.S. Food and Drug Administration (FDA) has granted eryaspase Fast Track designation for the treatment of acute ...</p>\n\n<a href=\"https://www.streetinsider.com/dr/news.php?id=18744154\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"DXCM":"德康医疗","TEAM":"Atlassian Corporation PLC","MSON":"Misonix Inc","SWKS":"思佳讯","ZYXI":"Zynex, Inc."},"source_url":"https://www.streetinsider.com/dr/news.php?id=18744154","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2155182860","content_text":"After-Hours Stock Movers:\nERYTECH Pharma (Nasdaq: ERYP) 140% HIGHER; announced that the U.S. Food and Drug Administration (FDA) has granted eryaspase Fast Track designation for the treatment of acute lymphocytic leukemia (ALL) patients who have developed hypersensitivity reactions to E. coli-derived pegylated asparaginase (PEG-ASNase).\nAtlassian (NASDAQ: TEAM) 13.2% HIGHER; reported Q4 EPS of $0.24, $0.06 better than the analyst estimate of $0.18. Revenue for the quarter came in at $560 million versus the consensus estimate of $524.09 million. Atlassian sees Q1 2022 EPS of $0.38-$0.39, versus the consensus of $0.31. Atlassian sees Q1 2022 revenue of $575-590 million, versus the consensus of $540.89 million.\nMisonix, Inc. (Nasdaq: MSON) 12% HIGHER; Bioventus Inc. (Nasdaq: BVS) (Bioventus), a global leader in innovations for active healing, and Misonix, Inc. (Nasdaq: MSON) (Misonix), a provider of minimally invasive therapeutic ultrasonic technologies and regenerative medicine that enhance clinical outcomes, today announced that they have entered into a definitive agreement by which Bioventus will acquire Misonix in a cash-and-stock transaction.\nZynex, Inc. (NASDAQ: ZYXI) 11% LOWER; reported Q2 EPS of $0.08, $0.02 better than the analyst estimate of $0.06. Revenue for the quarter came in at $31 million versus the consensus estimate of $31.31 million.\nZendesk (NYSE: ZEN) 7% LOWER; reported Q2 EPS of $0.13, $0.03 worse than the analyst estimate of $0.16. Revenue for the quarter came in at $318.2 million versus the consensus estimate of $319.79 million. Zendesk sees FY2021 revenue of $1.31-1.32 billion, versus the consensus of $1.31 billion. Zendesk sees Q3 2021 revenue of $332-337 billion, versus the consensus of $335.5 billion.\nSkyworks Solutions (NASDAQ: SWKS) 5.2% LOWER; reported Q3 EPS of $2.15, $0.01 better than the analyst estimate of $2.14. Revenue for the quarter came in at $1.12 billion versus the consensus estimate of $1.1 billion. Skyworks Solutions sees Q4 2021 EPS of $2.53-$2.48. Skyworks Solutions sees Q4 2021 revenue of $1.27-1.33 billion, versus the consensus of $1.22 billion.\nDexCom (NASDAQ: DXCM) 4.3% HIGHER; reported Q2 EPS of $0.76, $0.31 better than the analyst estimate of $0.45. Revenue for the quarter came in at $59.5 million versus the consensus estimate of $551.27 million. DexCom sees FY2021 revenue of $2.35-2.4 billion, versus the consensus of $2.34 billion.","news_type":1,"symbols_score_info":{"DXCM":0.9,"ERYP":0.9,"MSON":0.9,"SWKS":0.9,"TEAM":0.9,"ZEN":0.9,"ZYXI":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":808481353,"gmtCreate":1627606107372,"gmtModify":1633757877758,"author":{"id":"3583623112894486","authorId":"3583623112894486","name":"FuHeng","avatar":"https://static.tigerbbs.com/5ac797d3a7863e124a77bc5ad5f8cf1e","vip":1,"crmLevel":5,"crmLevelSwitch":0,"idStr":"3583623112894486","authorIdStr":"3583623112894486"},"htmlText":"Cool!","listText":"Cool!","text":"Cool!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/808481353","repostId":2155182860,"repostType":4,"repost":{"id":"2155182860","kind":"news","pubTimestamp":1627603020,"share":"https://ttm.financial/m/news/2155182860?lang=&edition=full","pubTime":"2021-07-30 07:57","market":"us","language":"en","title":"After-Hours Stock Movers: ERYTECH Pharma shares jumped 140%","url":"https://stock-news.laohu8.com/highlight/detail?id=2155182860","media":"StreetInsider","summary":"After-Hours Stock Movers:\nERYTECH Pharma (Nasdaq: ERYP) 140% HIGHER; announced that the U.S. Food an","content":"<p>After-Hours Stock Movers:</p>\n<p>ERYTECH Pharma (Nasdaq: ERYP) 140% HIGHER; announced that the U.S. Food and Drug Administration (FDA) has granted eryaspase Fast Track designation for the treatment of acute lymphocytic leukemia (ALL) patients who have developed hypersensitivity reactions to E. coli-derived pegylated asparaginase (PEG-ASNase).</p>\n<p>Atlassian (NASDAQ: TEAM) 13.2% HIGHER; reported Q4 EPS of $0.24, $0.06 better than the analyst estimate of $0.18. Revenue for the quarter came in at $560 million versus the consensus estimate of $524.09 million. Atlassian sees Q1 2022 EPS of $0.38-$0.39, versus the consensus of $0.31. Atlassian sees Q1 2022 revenue of $575-590 million, versus the consensus of $540.89 million.</p>\n<p>Misonix, Inc. (Nasdaq: MSON) 12% HIGHER; <a href=\"https://laohu8.com/S/BIOV\">Bioventus Inc.</a> (Nasdaq: BVS) (Bioventus), a global leader in innovations for active healing, and Misonix, Inc. (Nasdaq: MSON) (Misonix), a provider of minimally invasive therapeutic ultrasonic technologies and regenerative medicine that enhance clinical outcomes, today announced that they have entered into a definitive agreement by which Bioventus will acquire Misonix in a cash-and-stock transaction.</p>\n<p><a href=\"https://laohu8.com/S/ZYXI\">Zynex, Inc.</a> (NASDAQ: ZYXI) 11% LOWER; reported Q2 EPS of $0.08, $0.02 better than the analyst estimate of $0.06. Revenue for the quarter came in at $31 million versus the consensus estimate of $31.31 million.</p>\n<p>Zendesk (NYSE: ZEN) 7% LOWER; reported Q2 EPS of $0.13, $0.03 worse than the analyst estimate of $0.16. Revenue for the quarter came in at $318.2 million versus the consensus estimate of $319.79 million. Zendesk sees FY2021 revenue of $1.31-1.32 billion, versus the consensus of $1.31 billion. Zendesk sees Q3 2021 revenue of $332-337 billion, versus the consensus of $335.5 billion.</p>\n<p>Skyworks Solutions (NASDAQ: SWKS) 5.2% LOWER; reported Q3 EPS of $2.15, $0.01 better than the analyst estimate of $2.14. Revenue for the quarter came in at $1.12 billion versus the consensus estimate of $1.1 billion. Skyworks Solutions sees Q4 2021 EPS of $2.53-$2.48. Skyworks Solutions sees Q4 2021 revenue of $1.27-1.33 billion, versus the consensus of $1.22 billion.</p>\n<p>DexCom (NASDAQ: DXCM) 4.3% HIGHER; reported Q2 EPS of $0.76, $0.31 better than the analyst estimate of $0.45. Revenue for the quarter came in at $59.5 million versus the consensus estimate of $551.27 million. DexCom sees FY2021 revenue of $2.35-2.4 billion, versus the consensus of $2.34 billion.</p>","source":"highlight_streetinsider","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>After-Hours Stock Movers: ERYTECH Pharma shares jumped 140%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAfter-Hours Stock Movers: ERYTECH Pharma shares jumped 140%\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-30 07:57 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.streetinsider.com/dr/news.php?id=18744154><strong>StreetInsider</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>After-Hours Stock Movers:\nERYTECH Pharma (Nasdaq: ERYP) 140% HIGHER; announced that the U.S. Food and Drug Administration (FDA) has granted eryaspase Fast Track designation for the treatment of acute ...</p>\n\n<a href=\"https://www.streetinsider.com/dr/news.php?id=18744154\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"DXCM":"德康医疗","TEAM":"Atlassian Corporation PLC","MSON":"Misonix Inc","SWKS":"思佳讯","ZYXI":"Zynex, Inc."},"source_url":"https://www.streetinsider.com/dr/news.php?id=18744154","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2155182860","content_text":"After-Hours Stock Movers:\nERYTECH Pharma (Nasdaq: ERYP) 140% HIGHER; announced that the U.S. Food and Drug Administration (FDA) has granted eryaspase Fast Track designation for the treatment of acute lymphocytic leukemia (ALL) patients who have developed hypersensitivity reactions to E. coli-derived pegylated asparaginase (PEG-ASNase).\nAtlassian (NASDAQ: TEAM) 13.2% HIGHER; reported Q4 EPS of $0.24, $0.06 better than the analyst estimate of $0.18. Revenue for the quarter came in at $560 million versus the consensus estimate of $524.09 million. Atlassian sees Q1 2022 EPS of $0.38-$0.39, versus the consensus of $0.31. Atlassian sees Q1 2022 revenue of $575-590 million, versus the consensus of $540.89 million.\nMisonix, Inc. (Nasdaq: MSON) 12% HIGHER; Bioventus Inc. (Nasdaq: BVS) (Bioventus), a global leader in innovations for active healing, and Misonix, Inc. (Nasdaq: MSON) (Misonix), a provider of minimally invasive therapeutic ultrasonic technologies and regenerative medicine that enhance clinical outcomes, today announced that they have entered into a definitive agreement by which Bioventus will acquire Misonix in a cash-and-stock transaction.\nZynex, Inc. (NASDAQ: ZYXI) 11% LOWER; reported Q2 EPS of $0.08, $0.02 better than the analyst estimate of $0.06. Revenue for the quarter came in at $31 million versus the consensus estimate of $31.31 million.\nZendesk (NYSE: ZEN) 7% LOWER; reported Q2 EPS of $0.13, $0.03 worse than the analyst estimate of $0.16. Revenue for the quarter came in at $318.2 million versus the consensus estimate of $319.79 million. Zendesk sees FY2021 revenue of $1.31-1.32 billion, versus the consensus of $1.31 billion. Zendesk sees Q3 2021 revenue of $332-337 billion, versus the consensus of $335.5 billion.\nSkyworks Solutions (NASDAQ: SWKS) 5.2% LOWER; reported Q3 EPS of $2.15, $0.01 better than the analyst estimate of $2.14. Revenue for the quarter came in at $1.12 billion versus the consensus estimate of $1.1 billion. Skyworks Solutions sees Q4 2021 EPS of $2.53-$2.48. Skyworks Solutions sees Q4 2021 revenue of $1.27-1.33 billion, versus the consensus of $1.22 billion.\nDexCom (NASDAQ: DXCM) 4.3% HIGHER; reported Q2 EPS of $0.76, $0.31 better than the analyst estimate of $0.45. Revenue for the quarter came in at $59.5 million versus the consensus estimate of $551.27 million. DexCom sees FY2021 revenue of $2.35-2.4 billion, versus the consensus of $2.34 billion.","news_type":1,"symbols_score_info":{"DXCM":0.9,"ERYP":0.9,"MSON":0.9,"SWKS":0.9,"TEAM":0.9,"ZEN":0.9,"ZYXI":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":808412033,"gmtCreate":1627605793722,"gmtModify":1633757884249,"author":{"id":"4089010444435920","authorId":"4089010444435920","name":"lewisleeks","avatar":"https://static.tigerbbs.com/d39cf835a09bdd21dce8a780b993940c","vip":1,"crmLevel":1,"crmLevelSwitch":0,"idStr":"4089010444435920","authorIdStr":"4089010444435920"},"htmlText":"Great[Smile]&nbsp;","listText":"Great[Smile]&nbsp;","text":"Great[Smile]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/808412033","repostId":2155182860,"repostType":4,"repost":{"id":"2155182860","kind":"news","pubTimestamp":1627603020,"share":"https://ttm.financial/m/news/2155182860?lang=&edition=full","pubTime":"2021-07-30 07:57","market":"us","language":"en","title":"After-Hours Stock Movers: ERYTECH Pharma shares jumped 140%","url":"https://stock-news.laohu8.com/highlight/detail?id=2155182860","media":"StreetInsider","summary":"After-Hours Stock Movers:\nERYTECH Pharma (Nasdaq: ERYP) 140% HIGHER; announced that the U.S. Food an","content":"<p>After-Hours Stock Movers:</p>\n<p>ERYTECH Pharma (Nasdaq: ERYP) 140% HIGHER; announced that the U.S. Food and Drug Administration (FDA) has granted eryaspase Fast Track designation for the treatment of acute lymphocytic leukemia (ALL) patients who have developed hypersensitivity reactions to E. coli-derived pegylated asparaginase (PEG-ASNase).</p>\n<p>Atlassian (NASDAQ: TEAM) 13.2% HIGHER; reported Q4 EPS of $0.24, $0.06 better than the analyst estimate of $0.18. Revenue for the quarter came in at $560 million versus the consensus estimate of $524.09 million. Atlassian sees Q1 2022 EPS of $0.38-$0.39, versus the consensus of $0.31. Atlassian sees Q1 2022 revenue of $575-590 million, versus the consensus of $540.89 million.</p>\n<p>Misonix, Inc. (Nasdaq: MSON) 12% HIGHER; <a href=\"https://laohu8.com/S/BIOV\">Bioventus Inc.</a> (Nasdaq: BVS) (Bioventus), a global leader in innovations for active healing, and Misonix, Inc. (Nasdaq: MSON) (Misonix), a provider of minimally invasive therapeutic ultrasonic technologies and regenerative medicine that enhance clinical outcomes, today announced that they have entered into a definitive agreement by which Bioventus will acquire Misonix in a cash-and-stock transaction.</p>\n<p><a href=\"https://laohu8.com/S/ZYXI\">Zynex, Inc.</a> (NASDAQ: ZYXI) 11% LOWER; reported Q2 EPS of $0.08, $0.02 better than the analyst estimate of $0.06. Revenue for the quarter came in at $31 million versus the consensus estimate of $31.31 million.</p>\n<p>Zendesk (NYSE: ZEN) 7% LOWER; reported Q2 EPS of $0.13, $0.03 worse than the analyst estimate of $0.16. Revenue for the quarter came in at $318.2 million versus the consensus estimate of $319.79 million. Zendesk sees FY2021 revenue of $1.31-1.32 billion, versus the consensus of $1.31 billion. Zendesk sees Q3 2021 revenue of $332-337 billion, versus the consensus of $335.5 billion.</p>\n<p>Skyworks Solutions (NASDAQ: SWKS) 5.2% LOWER; reported Q3 EPS of $2.15, $0.01 better than the analyst estimate of $2.14. Revenue for the quarter came in at $1.12 billion versus the consensus estimate of $1.1 billion. Skyworks Solutions sees Q4 2021 EPS of $2.53-$2.48. Skyworks Solutions sees Q4 2021 revenue of $1.27-1.33 billion, versus the consensus of $1.22 billion.</p>\n<p>DexCom (NASDAQ: DXCM) 4.3% HIGHER; reported Q2 EPS of $0.76, $0.31 better than the analyst estimate of $0.45. Revenue for the quarter came in at $59.5 million versus the consensus estimate of $551.27 million. DexCom sees FY2021 revenue of $2.35-2.4 billion, versus the consensus of $2.34 billion.</p>","source":"highlight_streetinsider","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>After-Hours Stock Movers: ERYTECH Pharma shares jumped 140%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAfter-Hours Stock Movers: ERYTECH Pharma shares jumped 140%\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-30 07:57 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.streetinsider.com/dr/news.php?id=18744154><strong>StreetInsider</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>After-Hours Stock Movers:\nERYTECH Pharma (Nasdaq: ERYP) 140% HIGHER; announced that the U.S. Food and Drug Administration (FDA) has granted eryaspase Fast Track designation for the treatment of acute ...</p>\n\n<a href=\"https://www.streetinsider.com/dr/news.php?id=18744154\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"DXCM":"德康医疗","TEAM":"Atlassian Corporation PLC","MSON":"Misonix Inc","SWKS":"思佳讯","ZYXI":"Zynex, Inc."},"source_url":"https://www.streetinsider.com/dr/news.php?id=18744154","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2155182860","content_text":"After-Hours Stock Movers:\nERYTECH Pharma (Nasdaq: ERYP) 140% HIGHER; announced that the U.S. Food and Drug Administration (FDA) has granted eryaspase Fast Track designation for the treatment of acute lymphocytic leukemia (ALL) patients who have developed hypersensitivity reactions to E. coli-derived pegylated asparaginase (PEG-ASNase).\nAtlassian (NASDAQ: TEAM) 13.2% HIGHER; reported Q4 EPS of $0.24, $0.06 better than the analyst estimate of $0.18. Revenue for the quarter came in at $560 million versus the consensus estimate of $524.09 million. Atlassian sees Q1 2022 EPS of $0.38-$0.39, versus the consensus of $0.31. Atlassian sees Q1 2022 revenue of $575-590 million, versus the consensus of $540.89 million.\nMisonix, Inc. (Nasdaq: MSON) 12% HIGHER; Bioventus Inc. (Nasdaq: BVS) (Bioventus), a global leader in innovations for active healing, and Misonix, Inc. (Nasdaq: MSON) (Misonix), a provider of minimally invasive therapeutic ultrasonic technologies and regenerative medicine that enhance clinical outcomes, today announced that they have entered into a definitive agreement by which Bioventus will acquire Misonix in a cash-and-stock transaction.\nZynex, Inc. (NASDAQ: ZYXI) 11% LOWER; reported Q2 EPS of $0.08, $0.02 better than the analyst estimate of $0.06. Revenue for the quarter came in at $31 million versus the consensus estimate of $31.31 million.\nZendesk (NYSE: ZEN) 7% LOWER; reported Q2 EPS of $0.13, $0.03 worse than the analyst estimate of $0.16. Revenue for the quarter came in at $318.2 million versus the consensus estimate of $319.79 million. Zendesk sees FY2021 revenue of $1.31-1.32 billion, versus the consensus of $1.31 billion. Zendesk sees Q3 2021 revenue of $332-337 billion, versus the consensus of $335.5 billion.\nSkyworks Solutions (NASDAQ: SWKS) 5.2% LOWER; reported Q3 EPS of $2.15, $0.01 better than the analyst estimate of $2.14. Revenue for the quarter came in at $1.12 billion versus the consensus estimate of $1.1 billion. Skyworks Solutions sees Q4 2021 EPS of $2.53-$2.48. Skyworks Solutions sees Q4 2021 revenue of $1.27-1.33 billion, versus the consensus of $1.22 billion.\nDexCom (NASDAQ: DXCM) 4.3% HIGHER; reported Q2 EPS of $0.76, $0.31 better than the analyst estimate of $0.45. Revenue for the quarter came in at $59.5 million versus the consensus estimate of $551.27 million. DexCom sees FY2021 revenue of $2.35-2.4 billion, versus the consensus of $2.34 billion.","news_type":1,"symbols_score_info":{"DXCM":0.9,"ERYP":0.9,"MSON":0.9,"SWKS":0.9,"TEAM":0.9,"ZEN":0.9,"ZYXI":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"}],"hasMoreComments":true,"newsSizeData":{"likeSize":238,"commentSize":38,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false}}